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REGULATION OF ABCG5 AND ABCG8 STEROL TRANSPORTERS IN BILIARY CHOLESTEROL 
ELIMINATION, REVERSE CHOLESTEROL TRANSPORT AND DYSLIPIDEMIA 
 
ATP-binding cassette transporters ABCA1 and ABCG1 initiate reverse cholesterol 
transport generating HDL particles, whereas ABCG5/G8 promote biliary cholesterol 
secretion thereby facilitating the last step of reverse cholesterol transport. Mutations in 
the leptin axis result in obesity and dyslipidemia in ob/ob and db/db mice. These mice 
have defective HDL clearance, increased plasma cholesterol and decreased biliary 
cholesterol elimination. My studies demonstrate that ABCG5/G8 protein is low in these 
animals and can be restored with caloric restriction or leptin replacement. To directly 
test whether ABCG5/G8 alone is able to correct reverse cholesterol transport defect, 
liver specific ABCG5/G8 expression was achieved in db/db mice by administration of 
adenoviral ABCG5 and ABCG8. Restoration of biliary cholesterol is able partially to 
correct dyslipidemia in obese mice, but only in the presence of ezetimibe, an inhibitor of 
cholesterol absorption. 
 
ABCG5/G8 is the body’s primary defense against toxic effects of plant sterols. 
Plant sterols are used as cholesterol lowering food supplements. However, increased 
plasma plant sterol concentrations are associated with vascular lesions in dyslipidemic 
patients and animals. My in vitro studies demonstrate that individual plant sterol alter 
ABCA1 and ABCG1 abundance, cholesterol efflux and inflammatory cytokine secretion in 
macrophage foam cells at levels found in humans that consume plant sterol 
supplements.  
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Chapter 1:  GENERAL INTRODUCTION 
 
 
Sterols play indispensable roles in eukaryotic organisms. As a component of plasma and 
organelle membranes and as a precursor of essential molecules like steroid hormones, 
vitamin D and bile acids, cholesterol is the predominant sterol in mammals. Mammalian 
cells produce their own cholesterol and receive cholesterol by uptake from lipoproteins. 
Cells also continuously lose cholesterol to the outside circulation. Defects in synthesis, 
influx and efflux of cholesterol have devastating consequences for the individual. 
Genetic diseases such as desmosterolosis, Smith-Lemli-Opitz syndrome, Niemann-Pick 
C1 disease, Familial hypercholesterolemia, Tangier disease and sitosterolemia are 
examples of disorders caused by mutations in genes involved in cholesterol biogenesis, 
intracellular trafficking, cellular uptake and efflux. Conversely, excess cholesterol is the 
initial factor for the development of atherosclerosis and cardiovascular diseases (CVD). 
Hence, cellular and plasma cholesterol levels require strict regulation. 
 
 
Cholesterol structure, synthesis and metabolism 
Cholesterol is an isoprenoid which contains 4 fused hydrocarbon rings and a 
hydrocarbon side chain at C17 (Figure 1.1.). Cholesterol is a highly hydrophobic 
molecule with limited polarity due to the C3 hydroxyl group that determines cholesterol 
positioning within the lipid bilayer. The hydrophobic cholesterol property not only 
influences cell membrane fluidity, but also requires specific transport mechanisms in 
order to extrude cholesterol to the aqueous intra- and extracellular environment of the 
body [1]. 
 
Cholesterol synthesis is initiated by the formation of 3-hydroxy-3 methylglutaryl CoA 
(HMG-CoA) from acetyl CoA and acetoacetyl CoA and is mediated by HMG-CoA synthase 
(HMGS). HMG-CoA is reduced to mevalonate via HMG-CoA reductase (HMGR), the 
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enzyme responsible for the irreversible and rate limiting reaction in cholesterol 
synthesis [2]. Subsequently, mevalonate is converted to isoprenyl pyrophosphate, 
followed by a cascade of condensation reactions deriving the 30-carbon linear molecule 
of squalene that is finally cyclized to the steroid ring structure of lanosterol. The 
precursor of cholesterol, lanosterol, undergoes an additional 19 reaction steps in order 
to yield cholesterol.  
 
 
 
FIGURE 1.1. Cholesterol structure with standard carbon numbering organization. The 
conventional labels for rings according to IUPAC recommendations. 
 
Most of the cholesterol present in the body resides in cell membranes. The amphipathic 
molecule of cholesterol is placed in parallel to the fatty acid chains of the phospholipids 
and intercalates its polar hydroxyl group close to the phospholipid head group [1]. Due 
to its rigid structure, cholesterol increases lipid order and decreases fluidity of the cell 
membrane. Thus, membrane properties like permeability and stability, lipid raft 
formation and signal transduction are strongly influenced by cholesterol. 
 
 
Bile acid synthesis and metabolism 
Approximately 90% of the metabolized cholesterol in the body is converted to bile acids 
(~500 mg/day) [3]. Bile acid (BA) synthesis takes place in the liver and involves 17 
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different enzymatic reactions. The immediate products of bile acid synthesis are termed 
primary Bas. In humans these are predominantly cholic acid (CA) and chenodeoxycholic 
acid (CDCA) (Figure 1.2.), whereas in mice CA and muricholic acid are most abundant. 
Secreted from the bile into the intestine, primary BAs are converted by the anaerobic 
gut bacteria to secondary BAs – deoxycholic (DCA) and lithocholic (LCA) [4]. In contrast 
to hydrophobic cholesterol, the more hydrophilic BAs act as biological detergents and 
contribute to the absorption of dietary lipids and fat-soluble vitamins in small intestine. 
Individuals harboring mutations that result in BA deficiency suffer from lipid 
malabsorption and fat soluble vitamin deficiency [3]. 
 
 
 
FIGURE 1.2. Primary bile acids synthesized in murine liver. Cholic acid is the 
predominant product of the classical pathway, and muricholic acid is the prevalent 
derivate from the alternative pathway. 
 
 
The production of BAs from cholesterol involves more than one route. In the classical or 
neutral pathway, cholesterol 7α-hydroxylase (Cyp7a1) is the rate controlling enzyme 
converting cholesterol to 7α-hydroxycholesterol (7α-OH-C) [5-7]. The subsequent critical 
step of this route is the reaction mediated by 12α-hydroxylase (Cyp8b1). Since this 
enzyme is responsible for cholate production, the activity of Cyp8b1 determines the 
ratio between the cholate and muricholate [3].   
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The alternative pathway is associated with the conversion of cholesterol to oxysterols. 
In the liver, sterol 27 hydroxylase (Cyp27a1) accounts for the synthesis of 27 
hydroxycholesterol (27-OH-C) [5]. Studies in Cyp7a1 deficient mice revealed that 
approximately 25% of the BA pool originates from the alternative route [8]. By-products 
of this step are other oxysterols, 24- and 25-hydroxysterols (24-OH-C, 25-OH-C), which 
together with 27-OH-C are predominantly metabolized to muricholate.  
 
BA amphipathicity is increased and solubility is enhanced via conjugation to amino acids, 
e.g. taurine or glycine [9]. In the gut, surrounded by the intestinal flora, primary BAs 
undergo structural modification where CA is metabolized to LCA and CDCA is converted 
to DCA (secondary BAs) [4]. Approximately 95% of the BAs are recovered and enter the 
enterohepatic circulation, and the lost 5% are restored by the new synthesis in the liver.  
 
 
Plant sterols structure and metabolism in mammals 
Structurally similar to cholesterol, phytosterols (PS) are membrane constituents in 
plants and precursors for plant hormones and other secondary metabolites, i.e. sterol 
derivatives that play protective roles against pathogen and insect attack [10-12]. 
Whereas in mammals cholesterol is the prevalent sterol, in plants PS are always present 
in a mixture. The most prevalent PS are sitosterol and campesterol, which are identical 
to cholesterol in ring structure with a double bond between C5 and C6, but differ in 
their side chain by a methyl or ethyl group attached on the side chain at C24, 
respectively [13]. As demonstrated on Figure 1.3., brassicasterol and stigmasterol 
complicate their structure with a double bond at C22. Plant stanols vary from the 
corresponding sterols by the absence of a double bond between C5 and C6.  
 
PS are naturally present in the diet. In the typical Western type diet, plant sterols are 
almost equal to that of cholesterol (400mg/day). However, their poor absorption in the 
intestine (0.4-3.5%) compared to cholesterol (35-70%) ensures low concentrations of PS 
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in the plasma (0.2-1.0 mg/dL) [14]. PS have been recognized as dietary components with 
low density lipoprotein cholesterol (LDL-cholesterol) lowering properties in various 
populations and patient groups as early as 1951 [15, 16]. In the intestinal lumen PS 
compete with cholesterol for micellar solubilization and thereby interfere with 
cholesterol absorption and reduce plasma cholesterol levels [17]. 
 
 
 
FIGURE 1.3. Chemical structure of prevalent plant sterols compared to cholesterol. 
Plant sterols differ from cholesterol on the six carbon side chain by the group attached 
at C24 position and the double bond at C22.  
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Various studies in humans and animal models have shown that high levels of PS 
supplementation reduce plaque formation [18-22]. The reduction of atherosclerosis has 
been correlated with a decrease in plasma cholesterol levels in response to PS 
supplementation. However patients with sitosterolemia, a rare autosomal recessive 
disorder characterized by defective ATP-binding cassette (ATP) transporter ABCG5 
and/or ABCG8 and ~50 fold increased serum PS concentrations, often develop 
premature coronary heart disease (CHD) and accelerated atherothrombosis [23, 24]. 
Moreover, recent studies reported increased risk for CHD in non-sitosterolemic 
individuals with high plasma PS levels [25, 26]. In fact, it has been confirmed that 
different sterols provoke various physiological effects [27-30]. Chapter 4 discusses 
different actions of PS on macrophage functionality. 
 
Excess plant and mammal sterol in peripheral tissues, including macrophage foam cells 
in the vascular lesions, is moved through the plasma compartment to the liver. Hepatic 
cholesterol makes its way out of the body by conversion to primary BAs or is secreted as 
a free form. Each of these steps in cholesterol homeostasis is mediated by ABC 
transporters.  
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ATP-BINDING CASSETTE (ABC) TRANSPORTERS 
 
The ATP-binding cassette (ABC) transporters are a large family of proteins that hydrolyze 
adenosine triphosphate (ATP) and use this energy to transfer a large variety of 
substrates (metal ions, peptides, sugar, cholesterol and plant sterols, bile acids and 
phospholipids) across cellular membranes in bacterial and eukaryotic cells. Most 
mammalian ABC transporters harbor an ATP-binding region of approximately 100 amino 
acids where the Walker A and Walker B motifs are connected by a dodecapeptide 
sequence recognized as Linker region (C region) [31]. The Walker motifs are highly 
conserved and recognized as nucleotide binding domain (NBD). ABC transporters are 
associated with transmembrane (TM) domains containing six TM helices that are highly 
diverse among family members. Transporters that contain one ATP-binding site and one 
TM spanning domain are called half-transporters. However, functional transporters are 
composed of two NBDs and two TMs. Therefore, the ABC half-transporters act as 
homodimers (assembly with identical half-transporters) or heterodimers (assembly with 
different half-transporters) [32]. 
 
The human genome contains 48 ABC transporters, which are based on structure and 
homology. Classified into 7 subfamilies (A-G), in the following sections, transporters that 
have been implicated in the studies described in this thesis will be discussed. 
 
 
The ABCA-family 
ABCA1 (A1) is the most studied protein of the all 12 members of the ABCA-family. It is 
ubiquitously expressed, but is most prominent in enterocytes, hepatocytes and 
macrophages [33]. Mutations in ABCA1 cause the recessive disorder Tangier disease 
(TD) associated with severe high density lipoprotein (HDL) deficiency and cholesteryl 
ester accumulation in many tissues including tonsils, lymph nodes, liver, spleen and 
intestine [34, 35]. Hepatic and intestinal ABCA1 facilitates the transfer of phospholipids 
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and cholesterol to lipid poor nascent HDL (pre-β-HDL) and it is essential for the 
formation of “mature” or “spherical” HDL. This was best demonstrated in liver and 
intestinal-specific ABCA1 deficient mouse models, where a synthetic LXR agonist 
elevated HDL cholesterol levels regardless of the deletion [36, 37]. ABCA1 mediates lipid 
efflux to apoprotein A-I (apoA-I) in a two-step mechanism in which there is initial 
formation of an apoA-I complex, followed by lipidation of the bound apoprotein and 
dissociation of the resultant apoA-I /lipid complex [38, 39]. Hepatic and intestinal levels 
of apoA-I mRNA are normal in Tangier patients and ABCA1 deficient mouse models [40, 
41]. Studies demonstrate that exceptionally rapid catabolism but not defective synthesis 
of the apoprotein could explain the extremely low levels of HDL and apoA-I. 
 
Although liver and intestinal ABCA1 are responsible for the main production of HDL in 
the body, ABCA1 is critical for the efflux of excess cholesterol from macrophages and 
prevents the formation of foam cells, fatty streaks, and atherosclerotic plaques [42-44]. 
Hence, in Chapter 4 we evaluate ABCA1 expression, protein stability and function in 
mouse peritoneal and human macrophages after treatment with cholesterol lowering 
plant sterols. 
 
 
The ABCB-family 
The ABCB-family is also known as the multi-drug resistance/P-glycoprotein family. Two 
members of the ABCB-family, ABCB4 (B4) (Mdr2/MDR3) and ABCB11 (B11) (BSEP), are 
critical for lipid metabolism. They are predominantly expressed on the apical surface of 
hepatocytes and participate in bile formation.  
 
ABCB4 mRNA is found in spleen, adrenal gland, heart and muscle but its predominant 
role is in the liver [45]. ABCB4 P-glycoprotein is involved in the secretion of 
phospholipids from the canalicular membrane of the hepatocytes into the bile. The 
physiological role of the phospholipids is not only to solubilize biliary cholesterol in the 
 
9 
 
gallbladder but also to protect canalicular structures against the detergent action of bile 
salts. The Mdr2-/- mice which were used to study the functionality of the transporter, 
have normal secretion of BAs but severely damaged and inflamed bile duct [46, 47]. 
Patients with mutation in ABCB4 develop progressive familial intrahepatic cholestasis 
(PFIC) type 3 [48]. Moreover, the Mdr2-/- mouse model revealed the coupled secretion 
of phospholipids and cholesterol into the bile [49, 50].  
 
ABCB11, known as bile salt export pump (BSEP), is expressed on the apical surface of 
hepatocytes and transports BAs across the canalicular membrane [51, 52]. BA secretion 
is the main driving force for the secretion of phospholipids and cholesterol into the bile 
[53]. As the predominant component in bile, BAs form BA micelles, which are suitable 
acceptors for cholesterol secreted into the bile [54]. In humans disruption of ABCB11 
causes PFIC type 2 [55]. ABCB11 is a FXR/RXR target gene positively regulated by rising 
concentrations of bile salts in the liver, a protective mechanism against the toxic 
accumulation of bile salts [56, 57]. Gallbladder bile contains mixed micelles, which act as 
biological detergent in the lumen of the small intestine facilitating dietary cholesterol 
and fatty acid absorption in the gut. This is also the route used by cholesterol and bile 
acids to make its way out of the body. 
 
 
The ABCG-family 
Members of the ABCG-family are half-transporters that either for a heterodimer with 
each other like ABCG5 and ABCG8, or form homodimers like ABCG1, ABCG2, and ABCG4 
in order to become functionally active.  
 
ABCG1 is predominantly expressed in macrophages where it facilitates the efflux of 
excess cholesterol [58, 59]. As a liver X-receptor (LXR) target gene, ABCG1 mRNA and 
protein levels are upregulated upon cholesterol loading [58]. Conversely, cholesterol 
depletion and statin treatment downregulate expression of this transporter [60]. 
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Various studies demonstrate that ABCG1 stimulates cholesterol export to mature HDL, 
but not to lipid free apoA-I (like ABCA1) [61, 62]. Whereas, ABCA1 is responsible for the 
lipidation of lipid-poor apoA-I, ABCG1 participates in the lipid transfer to mature HDL 
[63, 64]. Deletion of ABCG1 leads to lipid accumulation in certain tissue macrophages, 
highlighting the important role of ABCG1 in cholesterol efflux [65]. However, 
independent studies have demonstrated that Abcg1-/- mice, in LDLR-/- background, have 
either decreased or increased atherosclerotic plaque formation [66-68]. In Chapter 4 we 
evaluate phytosterol effect on ABCG1 expression, protein stability and function in 
mouse peritoneal and human macrophages.  
 
ABCG5 and ABCG8 are expressed predominantly in liver, intestine and gallbladder [69, 
70]. Located at chromosome 2p21, Abcg5 and Abcg8 genes are situated in a head-to-
head orientation. In humans, their bidirectional common promoter region contains 374 
bp and assures their coordinate gene regulation [69, 71]. Mutations in either ABCG5 or 
ABCG8 result in sitosterolemia, an autosomal recessively inherited lipid metabolic 
disorder associated with increased deposition of PS and cholesterol in the coronary 
artery wall and in the skin as xanthomas [69, 70, 72, 73]. ABCG5 and ABCG8 are 
glycoproteins synthesized in the endoplasmic reticulum (ER) [74]. The lectin chaperone 
calnexin (CNX) associates with both half-transporters and mediates their proper protein 
folding [75]. Co-expression of both ABCG5 and ABCG8 in cultured cells or in the liver of 
ABCG5/G8 deficient mice results in ABCG5 and ABCG8 heterodimerization (ABCG5/G8), 
which is required for trafficking through the Golgi apparatus (GA) to the apical surface of 
hepatocytes or enterocytes [74, 76]. In intestine, ABCG5/G8 opposes the absorption of 
sterols. Free sterols are pumped from the intestinal epithelium into the gut lumen by 
ABCG5/G8, allowing predominant incorporation of cholesterol esters into chylomicrons 
(CMs) [69]. However, the selective elimination of PS by ABCG5/G8 is determined from 
acyl-CoA:cholesterol acyltransferase 2 (ACAT2). ACAT2, the main enterocyte cholesterol-
esterifying enzyme, has a lower affinity for PS than cholesterol [77]. In liver, ABCG5/G8 
mediates the excretion of free cholesterol into the bile. Hence, mice deficient in ABCG5, 
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ABCG8, or both transporters have an increase in dietary sterol absorption and a 
reduction in biliary cholesterol secretion [78-80]. Conversely, expression of a human 
transgene in wild type mice results in a 6–8 fold increase in biliary cholesterol 
concentration and supersaturation of bile [81].  
 
Activation of LXRα by cholesterol feeding or administration of LXR-agonists increases 
ABCG5 and ABCG8 mRNA as well as biliary cholesterol concentrations [82]. In addition, 
these effects are absent in mice lacking LXRα/β, suggesting that LXR is the principal 
regulator of ABCG5 and ABCG8 expression in response to dietary cholesterol [83]. 
Moreover, liver receptor homolog-1 (LRH-1), hepatocyte nuclear factor 4α (HNF4α), 
GATA, FOXO1 and FXR transcription factors control ABCG5 and ABCG8 transcriptional 
regulation [84-87]. Although the main steps involved in Abcg5 and Abcg8 nuclear 
regulation have been elucidated, little is known about ABCG5/G8 posttranscriptional 
control. 
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MOLECULAR REGULATION OF CHOLESTEROL METABOLISM BY NUCLEAR RECEPTORS 
 
Nuclear hormone receptors are transcription factors that regulate diverse physiological 
processes such as reproduction, development and whole body metabolism [88]. These 
receptors have a conserved DNA-binding domain (DBD), which recognizes 
corresponding DNA core sequences, called hormone response elements (HRE) in the 
gene promoter. The C-terminus of the receptor harbors the ligand binding domain (LBD) 
and participates in dimerization. The N-terminus contains a transcriptional activation 
function (AF-1) domain and mediates the association with co-repressors and co-
activators [89]. Generally, nuclear receptors are inactive when bound to co-repressors 
[89]. Following ligand binding, they undergo a conformational change, dissociate from 
the co-repressor, associate with a co-activator, dimerize with a partner and initiate 
transcription of the target gene. A number of nuclear receptors regulate key proteins 
and pathways in cholesterol absorption and elimination.  
 
 
The liver-X-receptors (LXR) 
The predominant nuclear receptor regulating cholesterol homeostasis is liver-X-
receptor, LXR. There are two LXR genes, LXRα expressed mainly in liver, macrophages, 
adipose tissue, lung, spleen and kidney, and the ubiquitously expressed LXRβ [90-92]. 
Oxysterols are the natural ligands of LXR. They are intermediates generated mainly from 
endogenous enzymatic reactions during cholesterol (24, 25-epoxycholesterol, 24, 25-EC) 
or steroid hormone biosynthesis (22-hydroxycholesterol, 22-OH-C), or compounds 
produced from cholesterol by different isoforms of cytochrome P450 (CYP) (24, 25, 27-
OH-C) [93].  
 
Cholesterol loading of the cell results in increased production of oxysterols, which 
stimulates LXR and upregulates the expression of ABCA1 and ABCG1 sterol transporters, 
enhancing cholesterol efflux from the plasma membrane to lipid-poor apoA-I and HDL, 
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respectively, thus providing a regulatory feedback mechanism maintaining a constant 
cholesterol content [94]. Multiple studies in various cell lines have demonstrated that 
LXR agonists (T0901317 and GW3965) increase ABCA1 and ABCG1 expression and 
accelerate cholesterol efflux [95-97].  
 
In liver, LXR target genes drive hepatic cholesterol elemination with cholesterol 
transport into the bile via ABCG5/G8 and stimulate bile acid synthesis via Cyp7a1 [82, 
98]. LXRα deficient mice do not activate Cyp7a1 or ABCG5/G8 expression when 
maintained on a cholesterol-rich diet [82, 99]. Conversely, T0901317 fails to increase 
biliary cholesterol secretion in ABCG5/G8 double knockout mice [83]. LXR agonists 
stimulate lipogenesis in hepatocytes. This effect is mediated by the sterol response 
element binding protein (SREPB) -1c transcription factor which harbors two LXR 
response elements within the promoter [100]. Subsequently, SREBP-1c binds to the 
SREBP response element (SRE) of genes involved in fatty acid synthesis. Independent 
from SREBP-1c, LXR directly regulates the expression of lipogenic enzymes such as 
acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), stearoyl-CoA desaturase (SCD-1) 
[101-103]. In addition, P. Tontonoz and colleagues demonstrated that LXR also monitors 
the delivery of cholesterol into the cell. LXR initiates degradation of LDLR through Idol 
(inducible degrader of LDLR)-dependent ubiquitination [104]. 
 
In intestine, LXR directly and indirectly opposes intestinal cholesterol absorption by 
ABCG5/G8 upregulation. LXR triggers a decrease in NPC1L1 localization on the apical 
surface of enterocytes and increased expression of ABCG5/G8 [82, 105]. Beyond its 
regulatory role in RCT, LXR may have a similar contribution in transintestinal cholesterol 
elimination (TICE) (discussed below). Indeed, GW3965 does not stimulate biliary 
cholesterol secretion, but increased fecal neutral sterol (FNS) loss in ABCB4 deficient 
mice [106]. The same compound was shown to increase radiolabelled cholesterol from 
plasma to the feces in the same model.  
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LXR also plays a role as a regulator of inflammation. By exerting anti-inflammatory 
effects, both LXR-agonists, T0901317 and GW3965 reduce LPS-induced expression of 
interleukin (IL)-6 and IL-1β in mouse peritoneal macrophages [107]. Conversely, LXRα/β 
deficient mice demonstrated greater susceptibility to lipopolysaccharide (LPS) 
administration increasing synthesis and circulation of tumor necrosis factor (TNF) α, IL-6 
and IL-1β compared to wild-type controls. Thus, when a macrophage engulfs cholesterol 
rich-material, LXRs are activated protecting the cell from lipid overload. Conversely, 
ingestion of material poor in cholesterol such as bacteria, LXRs remain inactive allowing 
inflammatory reactions to develop [107]. 
 
 
The farnesoid-X-receptors (FXR) 
Upon BA binding and activation, the BA sensor FXR heterodimerizes with RXR thereby 
controlling cellular BA levels [108-110]. FXR is expressed predominantly in liver and 
intestine, the two key organs involved in BA homeostasis [111]. BAs control their own 
synthesis by negative feedback via three independent pathways. Reabsorption of BAs 
from the ileum and their delivery to the liver activates hepatic FXR and elevates the 
expression of the FXR target gene SHP, which in turn inactivates liver receptor homolog 
1 (LRH-1), a transcription factor involved in Cyp7a1 expression. The result is SHP-
dependent transcriptional suppression of Cyp7a1 [112, 113]. In the second pathway, 
intestinal FXR activation increases the expression of fibroblast growth factor 15 (FGF15) 
in enterocytes. Secreted FGF15 binds to hepatic fibroblast growth factor receptor 4 
(FGFR4), activating c-Jun N-terminal kinase pathway (JNK) and ERK1/2 pathway and 
subsequently repressing Cyp7a1 [114]. Lastly, direct activation of JNK pathway via bile 
acids in the liver contributes to inactivate Cyp7a1 expression [115]. 
 
Hepatic FXR regulates the transcription of transporters involved in liver BAs uptake and 
excretion. Transcription of Na/taurocholate co-transporting polypeptide (NTCP), protein 
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responsible for uptake of bile acids from the blood compartment is suppressed by FXR 
via SHP [57]. Conversely, FXR upregulates transcription of proteins involved in bile acid 
export (ABCB11) including the phospholipid flippase, ABCB4, thereby protecting 
hepatocytes from bile salt toxicity and progression of intrahepatic cholestasis [56, 116].  
 
 
The liver receptor homolog (LRH-1) 
LRH-1 belongs to the nuclear receptor family 5A along with steroidogenic factor 1. 
Unlike other nuclear receptors, It binds to DNA as a monomer and does not require a 
ligand [117]. LRH-1 is found to be essential for embryogenic development [118]. It is 
expressed predominantly in the liver and intestine, but also in exocrine pancreas and 
ovaries [119, 120].  
 
LRH-1 participates in regulation of BA homeostasis. LRH-1 binding sites are found in the 
promoter of Cyp7a1 and Cyp8b1, enzymes controlling the initial steps in BA synthesis 
[112, 113, 121]. Lack of LRH-1 in the intestine represses FGF15 expression and sustains 
Cyp7a1 expression [118]. In addition, genes involved in cholesterol metabolism and 
transport, such as apoA-I, scavenger receptor class B type 1 (SR-B1) and ABCG5/G8 are 
positively regulated by LRH-1 in the enterohepatic axis [84, 122, 123].  
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ADDITIONAL TRANSCRIPTION REGULATORY FACTORS INVOLVED IN CHOLESTEROL 
METABOLISM 
 
Sterol regulatory element binding proteins (SREBPs) 
Additional group of oxysterols and sterol sensors (INSIG and SCAP) in the cell control the 
transcription of sterol regulatory element binding proteins (SREBPs). SREBPs are a family 
of membrane bound transcription factors that regulate the expression of genes involved 
in cholesterol and fatty acid synthesis. Three SREBPs have been described in mammals, 
SREBP-1a, -1c, and -2, where SREBP-1a and -1c are encoded by a single gene [124, 125]. 
SREBP-1c is highly expressed in mouse and human liver, white adipose tissue, adrenal 
gland and brain, whereas SREBP-1a and SREBP-2 are found in all tissues and in cultured 
cell lines [126, 127].  
 
SREBPs belong to the basic-helix-loop-helix-leucine zipper (bHLH-Zip) family of 
transcription factors. In contrast to the bHLH-Zip members, SREBPs are synthesized as 
inactive precursors bound to the endoplasmic reticulum (ER) [128, 129]. Each SREBP 
precursor harbors an NH2-terminal domain, which contains the bHLH-Zip region for 
binding DNA; two hydrophobic membrane-spanning segments connected by a short 30 
AA loop that projects into the ER lumen; and a COOH-terminal domain, which has 
regulatory activity and binds to an escort and sterol sensing protein designated as SCAP 
(SREBP cleavage-activating protein) [130]. When cells become cholesterol depleted, the 
SCAP/SREBP complex exits the ER and relocates in GA, where two membrane bound 
proteases, site 1 protease (S1P) and site 2 protease (S2P), cleave the precursor protein 
releasing the mature nSREBP into the cytoplasm. nSREBP translocates to the nucleus, 
where it activates transcription by binding to sterol response elements (SRE) in the 
promoter region of genes involved in cholesterol biosynthesis (HMGR) and cholesterol 
uptake (LDLR) [124, 125, 131]. When the cholesterol content of cells rises, cholesterol 
binds to SCAP and triggers conformational changes that induce the binding of SCAP to 
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ER residing protein INSIG-1 (insulin-induced-gene). Therefore, INSIG-1 controls 
cholesterol concentration in the cell through SREBP-2 [132].  
 
SREBP-1 transcription factors undergo similar processing mechanisms. However, SREBP-
1c transcription and processing of the mature precursor are controlled by insulin. In 
fasted state, where insulin is depleted, INSIG-2 is highly expressed, retaining SREBP-1c in 
the ER. In the presence of insulin, the fed state, INSIG-2 is strongly repressed by insulin 
[133]. SREBP-1c is actively processed to its nuclear form and converts excess 
carbohydrates to fatty acids activating genes involved in lipogenesis (ACC, FAS, SCD-1). 
In addition, nSREBP-1c recognizes SRE in INSIG-1 promoter and triggers gene expression, 
regulating indirectly cholesterol biosynthesis [134]. 
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CHOLESTEROL TRAFFICKING IN THE BODY 
 
Cholesterol is essential for cellular homeostasis, but dietary intake and cellular demand 
widely vary. Although, most cells have the capacity to make the cholesterol they need 
for membrane structural functions, some cells (steroidogenic cells and hepatocytes) that 
use cholesterol as a precursor for other molecules (steroid hormones and bile acids) and 
need an exogenous cholesterol supply [135]. Dietary lipids are delivered to the 
peripheral tissues by the TG-rich chylomicrons (CMs) upon remodeling of CMs by 
lipoprotein lipase (LPL) to CM remnant (CMR). Liver plays a central role in the clearance 
of cholesterol from the circulation. Further, liver is recognized as the main organ 
responsible for cholesterol distribution in the body. Several distinct pathways that can 
be distinguished are discussed below. 
 
 
Cholesterol flux in the enterocyte 
The intestinal lumen is exposed to exogenous dietary cholesterol (Western diet, 300-450 
mg/day) and endogenous biliary cholesterol (800 – 1400 mg/day) daily. Localized in the 
brush-border membrane of enterocytes, Niemann-Pick C1-like 1 (NPC1L1) is considered 
to be the main protein involved in intestinal cholesterol absorption [136]. Deletion of 
NPC1L1 or inhibition with ezetimibe (EZ) decreased total fractional sterol absorption and 
revealed that NPC1L1 does not distinguish dietary from biliary cholesterol and/or PS 
[137]. Nevertheless, NPC1L1 knockout mice display only partial reduction of cholesterol 
absorption, indicating an alternative pathway and suggesting more than one transporter 
may be involved. Placed on both apical and basolateral surface of enterocytes, 
scavenger receptor, class B, type 1 (SR-BI) was thought to contribute to the process 
[138]. However, disruption of the gene appears to have a negligible effect on intestinal 
cholesterol absorption in mice [139]. In addition, ABCA1 is also present on the 
basolateral membrane of the enterocytes and accounts for ~30% of the HDL biogenesis 
by transferring cholesterol to lipid poor pre-β-HDL [43].  
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FIGURE 1.4. Schematic description of the main routes of cholesterol trafficking in 
enterocytes. 
FC, free cholesterol; CE, cholesteryl ester; PL, phospholipid; PS, plant sterol; ABCA1, 
ABCG5, ABCG8, ATP binding cassette A1, G5, G8; ACAT, acyl-coenzyme A: cholesterol 
acyltransferase; HDL, high density lipoprotein; LDL, low density lipoprotein; LDLR, LDL 
receptor; LRP, LDLR related protein; SR-BI, scavenger receptor class B type 1; NPC1L1, 
Niemann-Pick disease type C1 gene-like 1; MTTP, microsomal triglyceride transfer 
protein; apoB-48, apolipoprotein B-48. 
 
 
In the enterocyte, acyl-coenzyme A: cholesterol acyltransferase 2 (ACAT2) targets the 
3’–OH (hydroxyl) group of cholesterol and esterifies fatty acids to form cholesteryl ester 
[140]. Approximately 50-60% of the intestinal cholesterol is esterified, packaged into 
chylomicrons (CMs), secreted into the mesenteric lymph and ultimately reaches the 
liver via plasma. PS are poor substrates of ACAT2. Consequently, they are poorly 
esterified and fail to be efficiently incorporated into CMs; therefore less than 1% enter 
into the circulation [141, 142]. Unesterified cholesterol and PS are recognized by 
ABCG5/G8 sterol transporters and excreted back into the intestinal lumen [69, 143]. In 
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addition, disruption of ABCG5/G8 diminishes excretion of cholesterol into the intestinal 
lumen and elevates fractional cholesterol absorption [78]. 
 
CMs are the major lipoprotein secreted by the intestine. CMs contain cholesterol ester 
(CE) and a predominantly triglyceride rich core surrounded by a monolayer of 
phospholipids, unesterified cholesterol and apolipoproteins (apoB-48, apoA-I, apoA-IV) 
[144]. CMs are secreted into the mesenteric lymph and reach the blood stream via the 
thoracic duct. In plasma, CMs incorporate additional apoproteins (apoE, apoCI, apoCIII). 
The CM triglyceride-rich core is hydrolyzed by LPL in the capillary endothelium, which 
releases free fatty acids for energy production or storage in the form of triglycerides in 
peripheral tissues (muscle, adipose) [145]. Consequently, triglyceride-rich CMs particles 
are transformed to CE-rich CMR, which are cleared by the liver by binding of apoE to 
LDLR or LDLR related protein 1 (LRP-1) [146, 147]. Therefore, biliary cholesterol 
absorbed from the intestine is returned to the liver.  
 
 
Hepatocytes cholesterol flux 
The liver is the principal organ involved in cholesterol regulation and metabolism in 
mammals. Cholesterol is delivered to the liver by apoE/apoB-48–containing CMR and 
LDL by LDLR and/or LRP-1 mediated endocytosis [146, 147]. Moreover, SR-BI found on 
the basolateral membrane of hepatocytes is involved in the selective uptake of 
cholesterol esters from HDL [148]. Cholesterol synthesis in the liver comprises a 
significant source of cholesterol in the hepatocytes.  
 
In the liver, cholesterol becomes part of different metabolic pathways (Figure 1.5.). 
Excess cholesterol in the liver can be stored as cholesterol ester after esterification by 
ACAT. Alternatively, cholesterol can be secreted into the blood stream in the free or 
esterified form via two apolipoprotein dependent routes - as HDL (discussed above) or 
VLDL, respectively. The VLDL particle is the predominant shuttle responsible for the 
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delivery of fatty acids and cholesterol from the liver to peripheral tissues. VLDL 
biogenesis is initiated by microsomal TG transfer protein (MTTP), an ER resident protein 
that mediates the transfer of lipids (triglycerides) to apoB-100 [149, 150]. Prior to a 
secretion into the blood, VLDL is enriched with triglyceride with a small amount of 
cholesterol ester in the core. Upon entering the circulation, the VLDL particles associate 
with apoE and apoC I-III. Similar to CMs, LPL hydrolyzes VLDL triglycerides forming 
smaller intermediate density lipoprotein (IDL). Further hydrolysis of IDL generates LDL, 
which is taken up by the liver or peripheral tissues via LDLR [146].  
 
 
Enterohepatic circulation 
As discussed above, free cholesterol in the liver is transported to the bile by the 
ABCG5/G8 heterodimer. In addition, cholesterol is converted to bile acids by Cyp7a1 
and excreted to the bile via ABCB11. The last pathways have been demonstrated to be 
coupled with phospholipid secretion into the bile by ABCB4. Deletion of the 
phospholipid transporter abolishes biliary cholesterol secretion [50]. Conversely, 
increased bile salt flux stimulates phospholipid and cholesterol translocation into the 
bile [46, 54]. Produced by hepatocytes, the bile contains BAs, cholesterol and 
phospholipids, organized into mixed micelles. Between meals, bile accumulates in the 
gallbladder. In response to a fatty meal, the gallbladder contracts and releases its 
components into the duodenum, promoting the solubilization, digestion and absorption 
of fat. Cholesterol and bile acids are absorbed in the intestine and re-enter the body, a 
cycle known as enterohepatic circulation. Whereas reabsorption of cholesterol occurs in 
duodenum, bile acids re-enter mainly in the ileum and return to the liver via the portal 
vein. Only a small part of the bile acids escapes reabsorption and is excreted into the 
feces. Cholesterol undergoes bacterial transformation in the intestine and is absorbed 
or excreted with feces [151]. 
 
 
 
22 
 
 
 
FIGURE 1.5. Overview of main routes of cholesterol in hepatocyte. 
FC, free cholesterol; CE, cholesteryl ester; BA, bile acid; PL, phospholipid; ABCA1, ABCB4, 
ABCB11, ABCG5, ABCG8, ATP-binding cassette A1, B4, B11, G5, G8; ACAT, acyl-coenzyme 
A: cholesterol acyltransferase; CEH, CE hydrolase; HDL, high density lipoprotein; VLDL, 
very low density lipoprotein; IDL, intermediate density lipoprotein; LDL, low density 
lipoprotein; LDLR, LDL receptor; LRP, LDLR related protein; SR-BI, scavenger receptor 
class B type 1. 
 
 
Reverse cholesterol transport (RCT) 
RCT is the process by which excess cholesterol from the peripheral tissues, including 
macrophages from the vessel walls, is transported to the liver for biliary excretion and 
eventually removed out of the body by the feces. HDL acts as cholesterol acceptor and 
carrier in RCT pathway by delivering its cholesterol the liver. The predominant HDL 
apoprotein, ApoA-I, is synthesized in the liver and intestine [152] and released as a 
discoidal lipid poor pre-β HDL particle which contains 2 copies of apoA-I [153]. ApoA-I 
concentrations correlate with HDL cholesterol levels in plasma. That was best 
demonstrated in ABCA1 transgenic mice, where overexpression of human apoA-I raised 
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HDL-cholesterol concentrations and provided protection against atherosclerosis [154]. 
Ubiquitously expressed ABCA1 facilitates efflux of free cholesterol and phospholipids 
from peripheral cells and macrophages to apoA-I, forming larger and more mature HDL 
[34, 155, 156]. Lecithin-cholesterol acyltransferase (LCAT) is an enzyme secreted from 
the liver, circulates in blood and associates with lipid free lipoproteins. LCAT reacts with 
free cholesterol and catalyzes the transfer of the 2-acyl group from lecithin to 3-β-OH of 
cholesterol to generate cholesteryl esters [157]. Cholesteryl esters are retained in the 
HDL core, forming the mature HDL particle. HDL metabolism is highly dependent on 
LCAT activity. LCAT deficiency in humans is associated with reduced HDL and ApoA-I 
levels and rapid catabolism of cholesterol ester-poor ApoA-I [158, 159].  
 
Mature HDL undergoes further remodeling by lipid transfer proteins, which are 
important determinants of HDL function and clearance. Cholesteryl ester transfer 
protein (CETP) promotes exchange of cholesteryl esters from HDL to and triglycerides 
within the lipoprotein core between HDL and ApoB containing particles (LDL, IDL, VLDL, 
CMs, and CMR) [160]. Thus, HDL is depleted of cholesterol and is enriched in 
triglycerides, whereas ApoB-lipoproteins incorporate cholesteryl esters. CETP-deficient 
patients are characterized by extremely elevated levels of HDL-cholesterol [161]. Unlike 
humans, mice lack the CETP gene. However, expression of a human CETP transgene 
significantly reduces HDL [162]. Phospholipid transfer protein (PLTP) delivers 
phospholipids to HDL from apoB-containing particles [163]. Disruption of PLTP in mice 
causes enhanced clearance of HDL and apoA-I and results in significant reduction of 
their levels [164]. 
 
Cholesterol delivery from HDL to the liver is another important step in RCT [165]. SR-BI, 
a member of the scavenger receptor superfamily of proteins, has been shown to play a 
major role in selective cholesterol uptake [166]. Mice deficient in SR-BI have elevated 
levels of HDL [167]. Conversely, overexpression of the receptor results in reduced 
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plasma concentrations, not only of HDL, but also of apoA-I, due to accelerated clearance 
of the particles after interaction with SR-BI [168-170]. 
 
 
 
FIGURE 1.6. Overview of Reverse cholesterol transport (RCT). 
FC, free cholesterol; CE, cholesteryl ester; PL, phospholipid; ABCA1, ABC-transporter A1, 
HDL, high density lipoprotein; SR-BI, scavenger receptor class B type 1, CMs, 
chylomicrons; VLDL, very low density lipoprotein; CETP, cholesterol ester transfer 
protein; PLTP, phospholipid transfer protein; LPL, lipoprotein lipase. 
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In addition to the hepatobiliary route, a body of literature has emerged within the last 
year describing an alternative pathway. Transintestinal cholesterol excretion (TICE) is 
now thought to play an important role for cholesterol elimination from the body [171]. 
Most of the studies were conducted in mouse models with impaired biliary cholesterol 
secretion. ABCB4 and ABCG5/8 knockout mice were characterized with a 6 fold decrease 
in biliary cholesterol concentrations, but no change in fecal sterol output compared to 
wild-type controls [106, 172]. Moreover, when challenged with the LXR agonist 
T0901317, ABCB4 deficient mice had an increase in fecal neutral sterol excretion but no 
induction of biliary cholesterol concentrations [173]. Conversely, NPC1L1 liver-specific 
transgenic mice have 4-20 fold decrease in biliary cholesterol but no change in fecal 
neutral sterols [174]. Although, there is strong evidence for the existence of TICE in 
mice, little is known about the molecular mechanisms involved in this alternative 
cholesterol elimination pathway [174, 175].  
 
 
 
HARMFUL EFFECTS OF CHOLESTEROL 
 
The hydrophobic characteristics of cholesterol obligate its incorporation into the 
hydrophobic core of water-soluble lipoprotein particles, which allows its trafficking 
through the aqueous environment of blood. Lipoproteins differ in their size, lipids and 
protein content, and the ratio of cholesteryl esters to triglycerides. CMs and VLDLs are 
large triglyceride-rich particles with very low density. The hydrolytic activity of LPL 
modifies VLDL to IDL and LDL, particles that become enriched in cholesterol as 
triglycerides are hydrolyzed. HDL is the smallest and most dense lipoprotein, which 
contains a cholesteryl ester-rich core with very little triglycerides. 
 
Disruptions of cholesterol metabolism cause increased plasma cholesterol 
concentrations. Accumulation of cholesterol in plasma is an independent predictor and 
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a risk factor for development of atherosclerosis and coronary heart disease (CHD) [176, 
177]. High levels of HDL have been associated with protective and beneficial effects, 
whereas high levels of LDL are associated with CVD [178]. When present in excess in the 
blood stream, cholesterol accumulates in the macrophages in the vessel wall, which 
causes fatty steaks formation that narrow and harden the arterial wall. As the build-up 
progresses, atherosclerotic lesions develop plaques, which can block the vessel or 
rupture and subsequently obstruct capillaries in the heart or in the brain [179]. 
Therefore, treatment of dyslipidemia is essential for prevention of CVD, a leading cause 
of death in the developed world.  
 
 
Cholesterol-lowering therapies 
Five main classes of therapeutic agents have been used for the treatment of 
dyslipidemia. Their primary focus is reduction of LDL-cholesterol and TGs, and 
normalizing the levels of HDL-cholesterol. Fibrates and niacin primarily target TGs and 
HDL-cholesterol, whereas bile acids sequestrants, statins and ezetimibe (EZ) focus on 
LDL-cholesterol. 
 
Bile acid sequestrants were one of the first classes of drugs used as cholesterol-lowering 
therapy and had effectively decreased the risk of cardiovascular disease (CAD) [180]. 
Bile acid sequestrants act in the small intestine, where they bind BAs and prevent their 
absorption thereby inhibiting the BAs enterohepatic circulation. This causes a significant 
increase of BAs bound to bile acid sequestrants in feces. Reduction of BAs in the liver 
upregulates the rate-limiting enzyme for conversion of cholesterol to BAs, Cyp7a1. The 
decline in cholesterol levels in liver increases the hepatic LDLR, which binds circulating 
LDL-cholesterol and results in a decrease in the level of circulating LDL-cholesterol [181]. 
However, cholesterol depletion in liver initiates cholesterol biosynthesis reducing the 
efficacy of this therapeutic. Bile acid sequestrants also inhibit cholesterol absorption by 
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preventing formation of micelles composed of BAs in the intestinal lumen, which may 
also contribute to the LDL-cholesterol lowering effect.  
 
Statins are by far the most powerful cholesterol lowering agents and reduce LDL-
cholesterol and prevent cardiovascular events. Statins inhibit the enzyme HMG-CoA 
reductase, thereby reducing endogenous cholesterol synthesis, causing a compensatory 
increase in LDLR expression [182]. Hepatic LDLR upregulation correlates with 
accelerated uptake and clearance of LDL [146]. Reduced free cholesterol content in 
hepatocytes activates SREBP-2 processing as discussed above. Numerous trials 
demonstrate their powerful efficacy in preventing cardiovascular outcomes [183]. 
 
Fibrates (or fibric acid derivatives) are agonists of peroxisome proliferator-activated 
receptor (PPAR) α, a transcriptional factor predominantly expressed in liver and muscle 
and highly involved in lipoprotein metabolism. PPARα activation targets the 
transcription of apoA-I and apoA-II, enhancing HDL biogenesis [184, 185]. Fibrate 
therapy has been associated with increased expression of acyl-coenzyme A synthetase 
(ACS) and fatty acid transport protein (FATP), which facilitate transport, acylation and 
subsequent β-oxidation of fatty acids and decreased triglyceride synthesis in the liver 
[186]. Fibrate treatment increases LPL expression and reduces LPL inhibitor, apoC-III, 
thereby increasing the hydrolysis of triglycerides in CMs and VLDL and improving their 
clearance from circulation by LDLR [187, 188].  
 
Niacin, nicotinic acid, is a water soluble B-complex vitamin used to treat dyslipidemia as 
early as 1955 [189]. Niacin is a hormone sensitive lipase (HSL) inhibitor in adipose tissue 
that reduces the transport of free fatty acid to the liver and reduces hepatic triglyceride 
synthesis [190]. In liver, niacin inhibits fatty acid-synthesis and esterification. The net 
effect is decreased triglyceride synthesis and increased ApoB-degradation [191]. VLDL 
production is reduced, which accounts for a reduction in LDL levels. In addition, niacin 
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elevates HDL by reducing hepatic apoA-I decay, but does not reduces cholesteryl ester 
clearance, thereby enhancing RCT [192].  
 
Ezetimibe (EZ, SCH 58235) is a cholesterol absorption inhibitor and blocks cholesterol 
absorption from the intestinal lumen into enterocytes [193]. The molecular target of 
ezetimibe is the sterol transporter, Niemann-Pick C1-like 1 protein (NPC1L1) [136, 194]. 
EZ lowers LDL‑cholesterol by blocking the intestinal absorption of dietary and biliary 
cholesterol without affecting TG or fat-soluble vitamins uptake [195]. Inhibition of 
NPC1L1 also impairs plant sterols intestinal absorption. EZ treatment of sitosterolemic 
patients produces significant and progressive reduction of plasma plant sterols 
concentrations [196]. 
 
CETP-inhibitors (torcetrapib, anacetrapib, dalcetrapib) prevent the exchange of 
cholesteryl esters of HDL with triglycerides of apoB-containing particles, blocking the 
CETP action. Thus, the amount of mature HDL particles is increased, while LDL-
cholesterol is reduced. Although Japanese subjects with homozygous CETP-deficiency 
have reduced incidence of CHD and increased life expectancy, the CETP inhibitor - 
torcetrapib did not prevent progression of carotid or coronary atherosclerosis more 
effectively than statins in clinical trials [197, 198]. Moreover, the same CETP-inhibitor 
induced side effects as increased blood pressure which possibly caused excess of 
cardiovascular and overall mortality [199]. Thus, it remains unclear what it will be the 
future of CETP-inhibitor for prevention and treatment of CVD. 
 
In the last two years a combinational therapy for hypercholesterolemia treatment 
began. Supplementation of two lipid-lowering drugs in a decreased dose regimen had a 
beneficial outcome on the side effects and targets different pharmacokinetic 
mechanisms which overall increases the efficacy of the therapeutics and has additive 
effects on plasma cholesterol lowering [200]. However, the hypercholesterolemic drug 
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combinational therapy needs more examination in order to provide consistent 
normalization of serum lipid profile and reduce the risk for CVD. 
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Chapter 2:  ROLE OF HEPATIC LEPTIN RECEPTOR SIGNALING IN REVERSE CHOLESTEROL 
TRANSPORT 
 
 
 
INTRODUCTION 
 
ABCG5 and ABCG8 play a major role in the elimination of dietary and endogenously 
synthesized sterols in humans and mice [69, 78-80, 201]. In intestine, the ABCG5/G8 
heterodimer opposes the absorption of biliary and dietary sterols [78, 143]. In liver, the 
ABCG5/G8 sterol transporter is the major route for cholesterol excretion into bile [78-
80]. Although biliary cholesterol excretion generally correlates with expression levels of 
ABCG5 and ABCG8 mRNAs, exceptions include increases in biliary cholesterol excretion 
following treatment with diosgenin or tauroursodeoxycholate (TUDCA) and in liver 
transplant patients following surgery [202-205]. The uncoupling of biliary cholesterol 
excretion from ABCG5/G8 expression levels suggests that other pathways may 
contribute to biliary cholesterol excretion. However, it should be noted that the effects 
of both diosgenin and TUDCA were dependent on the presence of G5G8 [205, 206], 
suggesting that post-transcriptional regulation of ABCG5/G8 may also influence 
ABCG5/G8 sterol transporter abundance and activity or that the pathways which supply 
cholesterol to the ABCG5/G8 sterol transporter can be regulated.  
 
Given the role of the ABCG5/G8 sterol transporter in biliary cholesterol excretion, 
perhaps it is not surprising that quantitative trait locus (QTL) mapping studies have 
identified Abcg5/Abcg8 as a lithogenic locus [207, 208]. However, the Abcg5/Abcg8 
locus is only one of over twenty QTLs associated with increased or decreased 
cholesterol gallstone susceptibility, indicating that many genetic factors are involved in 
lithogenesis [209]. Furthermore, ABCG5/G8 transgenic mice do not develop cholesterol 
gallstones despite supersaturation of bile [81]. In humans, obesity is considered a major 
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risk factor for cholesterol gallstone formation [210-213]. Surprisingly, two mouse 
models of obesity, leptin receptor defective (db/db) and leptin deficient (ob/ob), are 
protected from cholesterol gallstone formation when fed lithogenic diets that contain 
cholesterol and cholic acid [214]. Indeed, db/db and ob/ob mice have lower levels of 
biliary cholesterol than their wild-type counterparts [214, 215]. Replacement of leptin in 
ob/ob mice results in rapid weight loss, reductions in HDL-C, increases in biliary 
cholesterol concentrations and restoration of cholesterol gallstone susceptibility [216, 
217]. Although the same characteristics are also observed in mice that are pair-fed to 
match caloric intake, the control mice are still resistant to cholesterol gallstone 
formation, indicating that the 2-3 fold increases in biliary cholesterol concentrations are 
insufficient to promote gallstone formation.  
 
Leptin signaling-deficient animal models are characterized by dyslipidemia, insulin 
resistance, steatosis and inflammation. These metabolic disorders compromise liver 
function and may be responsible for reduced biliary cholesterol secretion. Within the 
liver, evidence of ER stress has been reported in both diet-induced obesity and in ob/ob 
mice [218]. Further, alleviation of endoplasmic reticulum (ER) stress by administration of 
chemical chaperones restores insulin sensitivity in ob/ob mice [219]. The assembly of 
the ABCG5/G8 sterol transporter occurs in the ER and is an inefficient process, whereby 
most of the ABCG5 and ABCG8 monomers fail to find their respective partners and are 
rapidly degraded [74]. Moreover, mutations in either ABCG5 or ABCG8 result in failures 
in the assembly and trafficking of the ABCG5/G8 sterol transporter and causes 
sitosterolemia [75]. The assembly of the complex is dependent upon N-linked glycans 
that interact with the ER chaperone Calnexin (CNX) [75]. Under conditions of ER stress, 
it is plausible that the assembly of the ABCG5/G8 sterol transporter is compromised.  
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Experimental Rationale 
Leptin-deficient (ob/ob) and leptin receptor defective (db/db) mice are animal models 
of obesity and dyslipidemia. In contrast to obese humans, db/db and ob/ob mice 
maintain low biliary cholesterol concentrations and are not susceptible to gallstones. 
We hypothesized that this phenotype correlates with a reduction in hepatic ABCG5/G8. 
ABCG5/G8 protein abundance was expected to be restored upon leptin or TUDCA 
administration, therapies known to accelerate biliary cholesterol content. 
 
 
EXPERIMENTAL PROCEDURES 
 
Reagents and Buffers: General chemical reagents were obtained from Sigma (St. Louis, 
MO). Recombinant murine leptin was obtained from Biomyx Technology (San Diego, 
CA). Protein Sample Buffer (PSB, 30 mM Tris base, 10 mM EDTA, pH 6.8, 3% SDS, 20% 
glycerol, 0.00625% bromophenol blue). Membrane Buffer (250 mM sucrose, 2 mM 
MgCl2, 20 mM, pH 7.5). Buffer A (20 mMTris, pH 7.6, 137 mM NaCl, 0.2% Tween 20, 5% 
milk). Buffer B (20 mM Tris, pH 7.6, 137 mM NaCl, 0.2% Tween 20). CNX, GRP78 were 
purchased from StressGen, Nventa (San Diego, CA). Secondary antibodies and enhanced 
chemiluminescence reagents were purchased from Pierce (Rockford, IL). Rabbit anti-
ABCG5 and mouse anti-ABCG8 antibodies have been previously reported [76, 81].  
 
Animals and Treatments: In the first experiment, male and female db/db mice on the 
C57BLKS (000642) background were used at 16 weeks of age. In all subsequent 
experiments, db/db (000697) and ob/ob (000632) mice on the C57BL/6J background 
were used between 8 and 12 weeks of age. All mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME). Animals were housed in a temperature-controlled room 
with 12:12 light:dark cycle (6:00 am to 6:00 pm). Upon arrival, mice were allowed to 
adapt to the environment for 1 week. All mice were maintained on standard rodent 
chow (Harlan Teklad 2014S). Analysis of the data from the first experiment indicated no 
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differential effects due to sex. In all subsequent experiments, male mice were used. 
Tissues from type I diabetic mice were generously provided by Dr. Ming Gong 
(University of Kentucky). STZ treatment was conducted as previously described [220]. 
Ob/ob mice were injected once daily with equal volumes of saline or leptin (10 µg/g bw, 
ip) for 7 days as previously described [217]. To achieve isocaloric intake, mice treated 
with saline were pair-fed with mice treated with leptin [217]. Mice treated with 
tauroursodeoxycholic acid (TUDCA) received twice-daily injections (ip, 7:00 am & 7:00 
pm) of 250 mg/kg (500 mg/kg/day) as previously described [219]. 
 
Blood glucose levels were measured using a standard glucometer from a drop of blood 
obtained by tail-vein prick. Control and STZ mice were killed by exsanguination under 
ketamine xylazine anesthesia. All others were euthanized with CO2 following a four hour 
fast beginning shortly after “lights on”. Blood was collected from the right ventricle with 
a 1 cc syringe fitted with a 20 ga hypodermic needle. Gall-bladder bile was collected 
with an insulin syringe fitted with a 26 ga needle. Bile samples were stored at -20oC until 
analysis. Serum was separated by centrifugation and stored at 4oC for fast protein liquid 
chromatography (FPLC) fractionation. Livers and other tissues were excised, rinsed with 
PBS to remove blood and snap frozen in liquid nitrogen. Tissue samples were stored at -
80oC until analyses.  
 
Lipid Analyses: Serum was fractionated by FPLC using Superose 6 HR10/30 column to 
separate lipoprotein fractions. Serum cholesterol concentrations and cholesterol 
content in FPLC fractions were determined by colorimetric-enzymatic assays (Wako 
Chemicals, Richmond, VA). The concentration of cholesterol in gallbladder bile was 
measured as previously described by GC-MS [221]. 
 
Membrane proteins analysis: A total of 100-200 mg of liver or intestine (duodenum, 
jejunum and ileum) was homogenized by a polytron in 1.2 ml Membrane Buffer 
containing protease inhibitors (Roche Diagnostics). The crude preparation was 
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centrifuged at 2000 x g for 10 min at 4oC. The supernatant was collected and centrifuged 
at 100,000 x g for 45 min at 4oC. The membrane pellet was suspended in PSB. Protein 
concentrations were determined by BCA assay (Pierce). PSB was added to samples to 
achieve uniform concentrations, β-mercaptoethanol was added to a final concentration 
of 1.2% (v/v) and samples were heated to 95oC for 5 min. Proteins were size 
fractionated on 10% SDS-polyacrylamide gels and transferred to nitrocellulose 
membranes. Membranes were incubated in Buffer A for 30 min at 22oC. Primary 
antibodies were diluted in Buffer A and incubated with membranes for 60 min at 22oC. 
Membranes were washed three times for 5 min in Buffer B. Horseradish peroxidase-
conjugated goat anti-rabbit IgG and goat anti-mouse IgG (Pierce) were diluted (1:20 
000) and incubated with membranes for 30 min at 22oC. Membranes were washed 
three times for 5 min in Buffer B and visualized by enhanced chemiluminescence 
(Pierce). Protein loading was assessed by visual inspection of Ponceau S-stained 
membranes and by re-blotting with GRP78 and CNX. Expression levels were semi-
quantified by densitometry. Radiography films were scanned as Tiff images and sum 
intensities quantified using KODAK Molecular Imaging software (V 4.0). Film background 
was subtracted from all bands of interest. Expression levels for ABCG5 and ABCG8 were 
normalized to signals for GRP78 obtained by re-blotting of stripped membranes. 
 
Quantitative Real-time PCR: Total RNA was extracted from tissues using RNeasy Mini Kit 
(QIAGEN, Valencia, CA). Samples of total RNA (1.0 µg) from mouse livers were 
transcribed using SuperScriptTMFirst Strand Synthesis System (Invitrogen, Carlsbad, CA, 
USA) using random hexanes in a final total reaction volume 20 µl. Primers (Table 1) have 
been previously described [222], but were validated to ensure amplification of single 
transcripts and covariance of amplification efficiencies with the invariant control 
(Cyclophilin) according to the manufacturer’s instructions (Applied Biosystems, Guide 
and User Bulletin 2). Quantitative RT-PCR was performed on an Applied Biosystem 7700 
Sequence Detection System. Standard reaction volume was 30 µl containing 1 x SYBR 
Green PCR master mix (Applied Biosystems), 1 µl of cDNA template 150 nM of each 
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oligonucleotide. Initial steps of RT-PCR were 10 min at 95oC. Cycles (n=40) consisted of a 
15 sec melt at 95oC, followed by a 1 minute annealing/extension at 60oC. All reactions 
were performed in triplicate. Means of the differences in threshold cycle (CT) values 
from cyclophilin and their standard deviations were calculated for each treatment group 
(ΔCT). The relative abundance of each transcript within treatment groups was 
determined by subtracting the control group mean difference from the remaining 
treatment groups (ΔΔCT) and calculated according to the expression 2
-ΔΔC
T. The standard 
deviations of the difference between control and each treatment group were calculated 
as the square root of the sums of squares for the standard deviation of the ΔCT means.  
 
 
TABLE 2.1:  Oligonucleotides used for quantative RT-PCT 
Target Forward Reverse 
ABCG5 TGGATCCAACACCTCTATGCTAAA GGCAGGTTTTCTCGATGAACTG 
ABCG8 TGCCCACCTTCCACATGTC ATGAAGCCGGCAGTAAGGTAGA 
LXRα TCTGGAGACGTCACGGAGGTA CCCGGTTGTAACTGAAGTCCTT 
SREBP-1c GGAGCCATGGATTGCACATT GGCCCGGGAAGTCACTGT 
Cyp7A1 AGCAACTAAACAACCTGCCAGTACTA GTCCGGATATTCAAGGATGCA 
 
Statistical Analysis: Data were analyzed by two-way, one-way, repeated measures one-
way analysis of variance (ANOVA) and Student’s t-test as indicated in text. Differences 
due to main effects and their interactions were determined by F-tests. Post-hoc 
analyses were conducted using Bonferroni or Dunnett’s Multiple Comparison Tests 
where appropriate.  
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RESULTS 
 
Steady-state levels of immunoreactive ABCG5 and ABCG8 were evaluated in livers of 
male and female db/db mice and their heterozygous controls (Figure 2.1). Db/db mice 
were significantly heavier (48 ± 5 vs. 28 ± 3 g) and had elevated fasting glucose levels 
(185 ± 18 vs. >475 mg/dl; four had values in excess of 500 mg/dl, the limit of the 
glucometer). Membrane proteins were prepared from livers of obese and control male 
and female mice (n=10 per genotype, 5 per sex) and subjected to SDS-PAGE and 
immunoblot analysis using antibodies directed against ABCG5 and ABCG8. For the 
purpose of presentation, equal amounts of membrane protein from each animal were 
pooled (Figure 2.1A). Two bands are routinely observed for both ABCG5 and ABCG8. The 
higher molecular weight, diffuse bands correspond to the post-Golgi forms of each 
protein whereas the lower molecular weight bands correspond to the reticular forms 
that have yet to heterodimerize and traffic to the cell surface. It should be noted that 
for ABCG5, the lower molecular weight band contains both specific and non-specific 
signals since it is also observed in ABCG5/G8 deficient mice [78]. GRP78 (Bip) expression 
was used to verify equal loading of proteins among lanes. Expression of CNX and CRT 
was also evaluated since previous reports indicate both ER lectins may be involved in 
the dimerization and folding of ABCG5/G8 (Figure 2.2.). Although no differences were 
observed for CRT, there appeared to be a modest reduction in the abundance of CNX.  
 
Additionally, ABCG2 (G2) and ABCA1 (A1) expression was also evaluated. ABCG2 is the 
most closely related member of the G-subfamily to ABCG5 and ABCG8. Like ABCG5 and 
ABCG8, it is a glycoprotein that forms a dimer within the ER prior to the transport of the 
functional complex to the apical surface, where it mediates excretion of dietary 
compounds into the biliary space [223, 224]. However, it is not involved in hepatobiliary 
transport of cholesterol and does not interact with either ABCG5 or ABCG8 [76, 225]. 
The expression of ABCG2 appears to be greater in male control mice than in the 
remaining three groups, but there were no differences between female control and 
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db/db mice, indicating that unlike reductions in ABCG5/G8, differences in ABCG2 could 
not be independently attributed to the presence of the db mutation. Like G5 and G8, 
ABCA1 expression is regulated by LXR. We evaluated the expression of ABCA1 by 
immunoblotting (Figure. 2.2.). In both male and female mice, ABCA1 levels were 
reduced when compared to lean controls. 
 
 
 
FIGURE 2.1. Expression of ABCG5 and ABCG8 and biliary cholesterol concentrations in 
wild-type (con) and db/db mice. A) ABCG5 (G5) and ABCG8 (G8) protein expression. 
The immature (reticular) and mature (post-Golgi) are noted by brackets. (*) denotes 
non-specific signals present in the ABCG5 immunoblot. Bip and ABCG2 were used as 
controls for equal protein loading and general effects on protein processing, n=5/group. 
B) Densitometric analysis of the signal intensities for ABCG5 and ABCG8 were 
normalized to the values obtained for Bip. C) The relative abundance of ABCG5 and 
ABCG8 mRNAs were quantified by RT-PCR. D) Cholesterol concentrations in gall-bladder 
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bile. Data represent the mean ± SD. (†) denote significant differences from control 
group at P < 0.05. 
 
 
 
 
FIGURE 2.2. ABCA1, Calnexin and Calreticulin expression in db/db mice. Pooled 
membrane preparations from livers of male and female db/db and their lean controls 
were analyzed by SDS-PAGE (50 μg/lane) and immunoblotting. 
 
 
Densitometric analysis of signal intensities for ABCG5 and ABCG8 was conducted for 
each mouse as described in methods. The data are expressed as the ratio of signal 
intensities for ABCG5 and ABCG8 to Bip (Figure 2.1B). The effect of genotype was 
significant for both ABCG5 and ABCG8 (p<0.01). However, there was no effect of sex or 
a genotype by sex interaction. In both male and female mice, levels of ABCG5 and 
ABCG8 were reduced between 50 and 60% in db/db mice compared to controls. ABCG5 
and ABCG8 protein levels were also determined in three segments of the small 
intestine. While there was a tendency for reduced protein levels in each segment, none 
reached statistical significance (not shown). To determine if the reduction in ABCG5 and 
ABCG8 protein was associated with a reduction in their respective mRNAs, total RNA 
was isolated and analyzed by quantitative RT-PCR (Figure 2.1C). The analysis indicates 
that there was no change in ABCG5 or ABCG8 mRNA levels. The data show that the 
reduction in ABCG5 and ABCG8 protein occurred in the absence of changes in mRNA for 
each half-transporter, indicating that differences in ABCG5 and ABCG8 protein levels 
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were not associated with a decrease in transcription. To determine if the reduction in 
ABCG5 and ABCG8 protein correlated with reduced biliary cholesterol concentrations, 
gall bladder bile was analyzed by GC-MS (Figure 2.1D). Bile was collected from control 
and db/db mice following a 4 hour fast beginning shortly after “lights on”. Cholesterol 
concentrations were reduced by 45% in db/db mice compared to controls (2.2 ± 0.53 vs. 
0.9 ± 0.56 mM).  
 
Like db/db mice, ob/ob mice harbor a deficiency in the leptin axis, are hyperphagic and 
obese. However, the defect in the leptin axis can be overcome by daily injections of 
recombinant leptin. For these experiments, I used a model of leptin replacement that 
has been shown to induce weight loss, restore plasma lipoprotein profiles and biliary 
cholesterol concentrations to wild-type levels [216, 217]. Four groups of mice (n = 3 per 
group) were compared. Wild-type control and ob/ob control mice were not treated. A 
second group of ob/ob mice received daily injections of recombinant leptin (10 
µg/g/day) for each of seven days. Because of leptin’s profound effect on food intake in 
ob/ob mice, a third group of ob/ob mice was treated with daily injections of the carrier 
(saline) for 7 days. Mice assigned to the saline group were pair-fed to mice receiving 
daily injections of leptin in order to achieve similar caloric intake and degrees of weight 
loss. Body weight was monitored daily in the ob/ob mice assigned to the leptin-treated 
and their pair-fed controls (Figure 2.3A). Body weight declined to a similar extent over 
the seven day period in these two groups of ob/ob mice indicating that caloric intake 
was similar in the two groups. 
 
Following a four hour fast after the last injection on day 7, mice were killed and tissues 
harvested for analysis. Serum cholesterol concentrations were greater in untreated 
ob/ob than in wild-type mice (Figure 2.3B, p<0.05). Leptin treatment reduced serum 
cholesterol concentrations in ob/ob mice (p<0.05) to levels similar to those observed in 
wild-type mice. There was also a tendency for reduced serum cholesterol in pair-fed 
mice, but it failed to reach statistical significance. FPLC analysis of pooled plasma 
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indicates that the reduction in serum cholesterol concentrations in leptin- treated and 
pair-fed controls was confined to the LDL containing fractions (13-18) and was slightly 
offset by modest increases in the HDL containing fractions (18-22, Figure 2.3C). 
 
 
 
FIGURE 2.3. Body weight and serum cholesterol levels in wild-type mice and ob/ob 
control and treated mice. A) Body weight was monitored over the seven day treatment 
period. B) Total serum cholesterol and C) relative cholesterol content in pooled, FPLC-
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fractionated serum from each group of mice, n=3/group. Data represent the mean ± SD. 
(†) denote significant differences from control group at P < 0.05. 
 
 
Immunoblot analysis of liver membrane preparations from wild-type and ob/ob mice 
confirmed results in db/db mice that indicate a reduction in ABCG5 and ABCG8 protein 
in mice harboring defects in the leptin axis (Figure 2.4A, densitometry not shown). 
Administration of leptin increased ABCG5 and ABCG8 protein in ob/ob mice to levels 
greater than those observed in wild-type mice. Immunoreactive ABCG5 and ABCG8 
levels were restored in ob/ob mice that were pair-fed to leptin-treated mice. 
Immunoreactive levels of ABCG2 were constant across all groups, indicating that global 
changes in protein synthesis and processing are insufficient to explain the reduction of 
ABCG5 and ABCG8 in ob/ob mice and their stabilization in leptin-treated and pair-fed 
mice. In addition, no differences were appreciated among treatment groups for CNX, 
CRT or ABCA1 (Figure. 2.5). While it is plausible that this difference could be due to 
differences between the two genotypes, it should be noted that the db/db mice were 
substantially older and had higher body weights and fasting glucose levels than the 
ob/ob mice. 
 
A one-way ANOVA indicated differences among treatment groups for biliary cholesterol 
concentrations. The reduction in immunoreactive ABCG5 and ABCG8 in untreated ob/ob 
mice relative to wild-type mice correlated with a reduction in biliary cholesterol 
concentration (Figure 2.4B). Conversely, the restoration of ABCG5 and ABCG8 either by 
leptin-treatment or calorie restriction in their pair-fed controls increased biliary 
cholesterol concentrations. However, the additional increase in ABCG5 and ABCG8 
protein levels following leptin treatment was not associated with a further increase in 
biliary cholesterol concentration. Finally, we evaluated the levels of ABCG5 and ABCG8 
mRNA (Figure 2.4C). As in db/db mice, there was no reduction in mRNA levels for either 
ABCG5 or ABCG8 in ob/ob mice compared to wild-type controls, indicating that the 
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reduction in ABCG5/G8 occurred post-transcriptionally. If anything, there is a modest 
increase, although these differences were not significant. 
 
 
 
Figure 2.4. Expression of ABCG5 and ABCG8 and biliary cholesterol in wild-type and 
ob/ob control and treated mice. A) ABCG5 (G5), ABCG8 (G8), ABCG2 (G2) and Bip 
protein immunoblotting analysis (n=3/group). B) Cholesterol concentrations in gall-
bladder bile. C) The relative expression of mRNAs as determined by RT-PCR, n=3/group. 
(*) denotes nonspecific band. Data represent the mean ± SD.  
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The expression of LXRα, SREBP-1c and Cyp7a1 was also evaluated. There is a modest, 
but consistent increase in LXRα, SREBP-1c, ABCG5 and ABCG8 mRNAs in ob/ob mice 
when compared to wild-type controls regardless of treatment. There was no change in 
Cyp7a1. When compared to untreated ob/ob mice, neither leptin treatment nor calorie 
restriction resulted in a significant increase in message levels for either ABCG5 or 
ABCG8. In conclusion, ABCG5 and ABCG8 protein levels are reduced in ob/ob mice and 
can be restored with either leptin replacement or dietary restriction, both of which 
increase biliary cholesterol content. However, changes in ABCG5 and ABCG8 protein 
levels and biliary cholesterol concentrations do not correlate with changes in mRNA 
levels for either transcript. 
 
 
 
Figure 2.5. ABCA1, Calnexin and Calreticulin expression in wild-type and ob/ob control 
and treated mice. Pooled membrane preparations from livers of male wild-type and 
ob/ob (control and treated) mice were analyzed by immunoblotting. 
 
 
Both db/db and ob/ob mice are obese, insulin resistant and routinely studied as a model 
of type 2 diabetes. Leptin treatment and dietary restriction are associated with 
increased insulin sensitivity. To determine if a lack of insulin signaling in the absence of 
obesity could explain the post-transcriptional reductions in ABCG5/G8, we evaluated 
levels of ABCG5 and ABCG8 in a mouse model of type I diabetes. Livers from control and 
streptozotocin (STZ) treated mice were generously provided by Dr. Ming Gong 
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(University of Kentucky). Membranes were prepared from livers and analyzed as in 
Figure 2.1 (Figure 2.6A). No differences in weights were detected between control and 
STZ treated mice; however, STZ treated mice were hyperglycemic (Figure 2.6B, C). 
Despite insulin insufficiency, there was no change in immunoreactive ABCG5 or ABCG8 
nor was there a compensatory increase in ABCG5 or ABCG8 mRNA (not shown). The 
results indicate that hyperglycemia and a lack of insulin signaling are insufficient to 
cause post-transcriptional reductions in the ABCG5/G8 sterol transporter. 
 
 
 
FIGURE 2.6. Expression of ABCG5 and ABCG8, body weight and blood glucose levels in 
control and diabetic (STZ) mice. A) ABCG5 (G5), ABCG8 (G8) and Bip immunoblotting 
analysis, (n=3/group). B) Body weights and C) blood glucose levels at the termination of 
the experiment. (*) denotes nonspecific band. Data represent the mean ± SD. (†) denote 
significant differences from control group at p < 0.05. 
 
 
Tauroursodeoxycholate (TUDCA) has been shown to increase the biliary excretion of 
cholesterol in the absence of changes in ABCG5 and ABCG8 mRNA levels [205]. 
Secondly, TUDCA has been shown to function as a molecular chaperone and was 
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recently reported to alleviate ER stress and hyperglycemia in ob/ob mice [219, 226]. 
Given that the ABCG5/G8 heterodimer is formed in the ER in a glycan-dependent 
manner that involves CNX, it has been hypothesized that TUDCA might increase biliary 
cholesterol excretion by stabilizing the ABCG5/G8 heterodimer in mice with defects in 
the leptin axis. To test this hypothesis we treated wild-type and db/db mice with either 
PBS (control) or TUDCA. 
 
 
 
Figure 2.7. Body weight, blood glucose and serum cholesterol levels in control and 
TUDCA treated wild-type and db/db mice. A) Body weight, B) blood glucose, and C) 
serum cholesterol levels. D) Relative cholesterol content in pooled, FPLC-fractionated 
serum from each group. Data represent the mean ± SD. (†) denote significant 
differences at P < 0.05.  
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Body weight and plasma glucose concentrations were analyzed using two-way repeated 
measures ANOVAs. For body weight, there were no differences between weights on Day 
1 and Day 10 within any of the treatment groups (Figure 2.7A). For blood glucose, the 
treatment by time interaction tended to be significant (p=0.07). A post-hoc analysis 
indicated that plasma glucose levels were lower on day 10 than on Day 1 in db/db mice 
treated with TUDCA, but not in db/db control mice (Figure 2.7B). However, it should be 
noted that recorded plasma glucose levels declined slightly in PBS treated mice, 
elevating the P-value for the treatment by time interaction. Plasma cholesterol data was 
analyzed using a two way ANOVA comparing genotype, treatment with TUDCA and their 
interaction (Figure 2.7C). Although genotype was associated with a modest, but 
significant increase in plasma cholesterol levels (p<0.05), significant differences were 
not detected for treatment or the treatment by genotype interaction. FPLC fractionation 
of pooled serum confirmed the elevations in serum cholesterol concentrations were 
largely due to increases in LDL containing fractions, although HDL containing fractions 
also had increased cholesterol content (Figure 2.7D). 
 
Immunoblot analysis indicates that TUDCA increased ABCG5 and ABCG8 protein levels in 
both wild-type and db/db mice (Figure 2.8A). Consistent with previous observations, 
biliary cholesterol concentrations were lower in control, db/db mice compared to wild-
type controls (Figure 2.8B). TUDCA treatment was associated with increased biliary 
cholesterol concentrations regardless of genotype; however, the genotype by treatment 
interaction was not significant, indicating that TUDCA increased biliary cholesterol 
concentrations irrespective of genotype. Interestingly, the expression of ABCG2 appears 
to be modestly reduced in db/db mice when compared to controls, an observation that 
is consistent with that observed in Figure 2.1. However, levels of ABCG2 were not 
affected in either wild-type or db/db mice by treatment with TUDCA, indicating that the 
effects of TUDCA show some degree of specificity. CNX, CRT and A1 were neither 
affected by genotype nor treatment with TUDCA (Figure 2.9).  
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Figure 2.8. Expression of ABCG5 and ABCG8 and biliary cholesterol concentrations in 
control and TUDCA-treated wild-type and db/db mice. A) ABCG5 (G5), ABCG8 (G8), 
ABCG2 (G2) and Bip immunoblotting analysis. B) Biliary cholesterol concentrations. C) 
The relative expression of mRNAs as determined by RT-PCR. (*) denotes nonspecific 
band. Data represent the mean ± SD.  
 
 
Lastly, I evaluated mRNAs for ABCG5, ABCG8, LXRα, SREBP-1C and Cyp7A1 (Figure 2.8C). 
Consistent with earlier studies, there were no changes in ABCG5 and ABCG8 mRNAs 
between wild-type and db/db mice, nor were there differences in LXRα or Cyp7A1. As 
expected, db/db mice have elevated mRNAs encoding SREBP-1c; treatment with TUDCA 
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suppressed Cyp7A1 mRNA in both genotypes. In conclusion, TUDCA increased ABCG5 
and ABCG8 protein levels and biliary cholesterol concentrations in both wild-type and 
db/db mice independently of changes in mRNA levels for either protein. 
 
 
 
Figure 2.9. ABCA1, Calnexin and Calreticulin expression in control and TUDCA-treated 
wild-type and db/db mice. A) Membrane preparations from livers of male untreated 
(PBS) and TUDCA-treated wild-type and db/db mice were analyzed by immunoblotting. 
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DISCUSSION 
 
The major findings of this study are that defects in the leptin axis are associated with 
reductions in the levels of immunoreactive ABCG5/G8 sterol transporter. These 
reductions are not associated with decreased levels of mRNAs encoding either subunit. 
The reduction in ABCG5/G8 sterol transporter levels can be restored with caloric 
restriction and further enhanced by leptin replacement. Similarly, administration of 
TUDCA can restore immunoreactive ABCG5 and ABCG8 in db/db mice, but also increases 
ABCG5/G8 in wild-type mice. For caloric restriction, leptin-replacement and TUDCA-
treatment, the increases in ABCG5/G8 abundance are associated with increased biliary 
cholesterol concentrations.  
 
Beyond the absence of a functional leptin axis, the molecular mechanism for the post-
transcriptional reduction in ABCG5/G8 transporter levels in db/db and ob/ob mice is not 
known. A number of possibilities exist and include a decrease in the rate of translation, 
assembly of the complex within the ER, and stability of the post-Golgi complex. Studies 
in cell culture indicate that the bulk of ABCG5 and ABCG8 monomers fails to find their 
respective partners and are rapidly degraded [74]. This may also be true in vivo, since 
the reticular forms of both ABCG5 and ABCG8 have half-lives of approximately two 
hours and are generally visible in immunoblots of hepatic and intestinal membrane 
preparations. A recent report indicates that expression of CRT can facilitate the 
trafficking of ABCG5/G8 transporters to the cell surface, suggesting that chaperone 
activity can be both limiting and overcome experimentally [227]. I evaluated the 
expression of CNX and CRT in these experiments. In the first experiment, CNX levels 
were modestly reduced. However, in subsequent experiments this finding was not 
reproducible. There are significant differences between the db/db mice used in the 
experiment presented in Figure 2.1 and the remainder of the studies that may account 
for the differences in CNX expression. First, the mice are on the KS strain of C57Bl/6 
mice. Secondly, they were considerably older and had greater fasting glucose levels. 
 
50 
 
Regardless of these differences, reductions in ABCG5/G8 abundance and biliary 
cholesterol concentrations are consistent across all experiments, indicating that reduced 
CNX expression in older db/db mice is insufficient to explain the reduction in ABCG5/G8 
abundance and activity. 
 
Although diabetes in the absence of leptin deficiency failed to reduce ABCG5/G8 
transporter levels, calorie restriction in ob/ob mice largely restored levels of the 
complex. This effect is presumably metabolic in nature and may be due to a reduction in 
hepatic ER stress. A recent study indicates that alleviation of ER stress is sufficient to 
correct hyperglycemia in ob/ob mice [219]. In the present study, we treated db/db mice 
with TUDCA using the same treatment paradigm previously reported. We did see a 
reduction in plasma glucose levels in db/db mice when comparing Day 1 to Day 10 of 
treatment in post-hoc analysis. In addition, we saw an increase in ABCG5/G8 
transporters compared to control, db/db mice indicating that TUDCA treatment was 
sufficient to correct the effect of leptin deficiency on ABCG5/G8 levels. Interestingly, the 
effect of TUDCA was also observed in wild-type mice. This observation suggests that 
chaperone activity may be limiting in wild-type mice and supports in vitro data 
suggesting that a significant number of ABCG5 and ABCG8 monomers fail to reach their 
final destination. However, the interpretation of the effect of TUDCA on ABCG5/G8 is 
limited by the fact that the mechanism by which TUDCA acts as a molecular chaperone 
is not known and its ability to suppress Cyp7a1, presumably via FXR, indicates that the 
molecule elicits responses beyond its effects as a molecular chaperone. Further, TUDCA 
has been shown to acutely increase biliary cholesterol secretion when infused into mice 
[228]. It is unlikely that this effect involved alterations in the assembly of ABCG5/G8 
transporters via chaperone activity, although these experiments cannot preclude this 
possibility. Furthermore, feeding cholate to mice has been shown to increase both 
ABCG5/G8 abundance and mRNA, an effect lost in FXR deficient mice [202]. A careful 
study of the effects of individual bile acids on complex synthesis, assembly and 
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transport will be required to elucidate the mechanisms by which they influence activity 
of the ABCG5/G8 transporter. 
 
The effect of leptin on ABCG5/G8 is not entirely explained by caloric restriction and 
weight loss. The dose of leptin used in the present study increased ABCG5/G8 to levels 
greater than those observed in wild-type mice. However, this increase was not 
associated with a further increase in biliary cholesterol concentrations. This observation 
is largely consistent with those of Cohen and his colleagues which show that while leptin 
infusion increases biliary cholesterol concentrations relative to untreated ob/ob mice, 
pair-feeding mice to match caloric intake with those receiving leptin also increases 
biliary cholesterol secretion [216, 217]. In these studies, biliary cholesterol 
concentrations in pair-fed mice were greater than those observed in leptin-treated mice 
evaluated after 14 days of leptin replacement on control or lithogenic diets. The 
uncoupling of ABCG5/G8 protein levels with biliary cholesterol concentrations suggests 
that ABCG5/G8 transporter activity is regulated beyond abundance of mRNA and 
protein. These may include pathways that supply cholesterol to the transporter, alter 
the subcellular localization of ABCG5/G8 or directly affect transport activity within the 
canalicular membrane. Although such mechanisms have yet to be reported, the present 
study cannot preclude their involvement.  
 
 
 
 
 
 
 
 
 
Copyright © Nadezhda S. Sabeva 2011  
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Chapter 3:  LIVER SPECIFIC EXPRESSION OF ABCG5/G8 REQUIRES INHIBITION OF 
CHOLESTEROL ABSORPTION TO REDUCE PLASMA CHOLESTEROL IN DYSLIPIDEMIC 
DB/DB MICE 
 
 
 
INTRODUCTION 
 
Metabolic syndrome is a constellation of risk factors that includes obesity, 
hypertriglyceridemia, insulin resistance, and low high density (HDL) cholesterol that 
collectively contribute greater increased risk for cardiovascular diseases (CVD) than their 
sum [229]. Virtually all of these are also independent risk factors of gallbladder disease 
[230]. Mice that are homozygous for spontaneous mutations in either the gene 
encoding leptin (ob/ob) or its receptor (db/db) are obese, insulin resistant and 
hypertriglyceridemic [231]. However, these strains have a unique dyslipidemia 
characterized by the accumulation of large, cholesterol enriched HDL [232]. While the 
phenotype is leptin-dependent, the mechanisms responsible for the development of 
this unique dyslipidemia remain unclear. 
 
HDL is considered to be atheroprotective based on a variety of beneficial effects on 
vascular function, plasma lipids and its multiple roles in the reverse cholesterol 
transport (RCT) pathway [233]. HDL acts as an acceptor for cholesterol in peripheral 
tissues as well as a donor of cholesterol to the liver, either directly or through other 
plasma lipoproteins. SR-BI is a class B scavenger receptor that binds HDL, mediates the 
selective delivery of cholesterol esters to cells, and is a major determinant of plasma 
HDL levels in both humans and mice [165, 167, 234, 235]. SR-BI also plays a central role 
in biliary excretion of cholesterol. The absence of SR-BI reduces biliary cholesterol 
concentrations; whereas adenoviral mediated overexpression of SR-BI increases biliary 
cholesterol excretion and lowers plasma HDL [168, 170, 236]. Using polarized 
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hepatocytes, McPherson and colleagues showed that SR-BI could bind HDL and deliver it 
to the subcanalicular domain [237]. The excretion of cholesterol into bile is largely 
dependent upon the activity of the ABCG5/G8 sterol transporter [78, 238]. This complex 
is thought to function at the apical surface of hepatocytes and promote the enrichment 
of cholesterol in the outer leaflet of the canalicular membrane [74, 239]. ABCG5/G8 is 
also expressed in the small intestine where it opposes the absorption of dietary sterols 
[78, 238]. Effective opposition to accumulation of dietary cholesterol appears to require 
both hepatic and intestinal ABCG5/G8. Mice harboring a human ABCG5/G8 transgene 
under the control of the endogenous promoter is expressed in both liver and intestine 
and opposes cholesterol accumulation in LDLR deficient mice, whereas a liver specific 
transgenic ABCG5/G8 fails to prevent cholesterol accumulation unless cholesterol 
absorption is inhibited [78, 240]. 
 
The unique dyslipidemia associated with leptin deficiency may be caused by alterations 
in HDL structure, SR-BI function or impaired hepatobiliary cholesterol transport by 
ABCG5/G8. HDL particles obtained from ob/ob mice are larger, enriched in apoA-II, and 
demonstrate delayed clearance in the plasma of obese compared to lean mice [232]. SR-
BI is either reduced or unchanged in leptin deficient mice [232, 241]. In Chapter 2 it was 
demonstrated that ABCG5/G8 expression is post-transcriptionally reduced in both 
ob/ob and db/db mice. Leptin replacement in ob/ob mice restores biliary cholesterol 
elimination, increases both SR-BI and ABCG5/G8 protein, and normalizes plasma HDL 
[216, 241, 242]. 
 
 
Experimental rationale 
 
Ob/ob and db/db mice are models of obesity and dyslipidemia, known to have defects 
in the leptin axis, defective HDL clearance, increased plasma cholesterol and decreased 
biliary cholesterol concentrations associated with reduction in ABCG5/G8 proteins. I 
 
54 
 
hypothesized that the disruption in hepatobiliary cholesterol excretion may impact SR-BI 
levels or function, and consequently plasma HDL levels. To test this hypothesis, I 
restored biliary cholesterol excretion with adenoviral vectors encoding ABCG5 and 
ABCG8 in db/db mice. Based on the possible concern that a significant portion of the 
excreted cholesterol would be reabsorbed in the intestine and mitigate the effects of 
hepatic ABCG5/G8, the experiment was conducted in the presence and absence of EZ. 
Expression of ABCG5/G8 was expected to increase biliary cholesterol and fecal neutral 
sterol (FNS) excretion, and normalize plasma cholesterol levels.  
 
 
EXPERIMENTAL PROCEDURE 
 
Reagents and Buffers: General chemical reagents were purchased from Sigma (St. Louis, 
MO). Serum, triglycerides and phospholipids measurements used colorimetric-
enzymatic assay kits (Wako Chemicals USA Inc., Richmond, VA). MBST/OG was used in 
hepatic lipid extraction (0.97% 2-(N-morpholino) ethanesulfonic acid, 1.7% NaCl, 2% 
Triton X-100 and 3.5% Octylglucopyrannoside). The rest of the reagents and buffers are 
as reported in Chapter 2. 
 
Animals and Treatments: Male db/db mice on C57BL/6J background at 32 weeks of age 
were used in these studies. All mice were obtained from Jackson Laboratory (Bar 
Harbor, ME) and maintained in the same conditions as specified in Chapter2. Mice were 
maintained on standard rodent chow diet (Harlan Teklad 2014S) or chow diet 
supplemented with EZ (0.005% w/w), where specified. Diets were formulated by 
Research Diets Inc. (New Brunswick, NJ). 
 
Adenovirus treatment: Recombinant adenoviral vectors containing cDNAs for ABCG5 
and ABCG8 have been described previously [74, 76]. Briefly, the viruses were 
propagated in HEK-293 cells, purified using AdEAsy Virus Purification Kits, Stratagene (La 
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Jolla, CA). Viral titer was quantified by Adeno-X Rapid Titer Kit, Clontech (Mountain 
View, CA). On Day -4 of the experiment, two db/db groups (n=3) were provided 
standard chow diet or chow supplemented with ezetimibe (0.005%). On Day 0, mice 
were placed in clean cages and injected (i.v., tail vein) with a cocktail of adenoviruses 
encoding both ABCG8 and ABCG5 in a 2:1 ratio (5 × 108 particles/kg total virus). Pilot 
studies indicate that this ratio optimizes the appearance of the mature, post-Golgi forms 
of both ABCG5 and ABCG8 and is the minimal dose capable of increasing biliary 
cholesterol concentrations (not shown). After 72 hours (Day 3), the animals were 
anesthetized with ketamine:xylazine anesthesia after a 4 hr fast beginning shortly after 
“lights on”. Blood, gallbladder bile, tissues and feces were collected and analyzed. 
Tissues were snap frozen in liquid nitrogen and stored at -80°C until processing for 
membrane preparation, SDS-PAGE, immunoblot analysis and qRT-PCR. 
 
Lipid analysis: The total concentration of cholesterol in gallbladder bile was analyzed by 
GC-MS/FID. Briefly, 10 μl of bile were placed into a glass tube together with 5α-
cholestane. Lipids were saponified for 2 hrs at 90-100°C in hydrolysis solution (6% KOH 
10 M stock solutions dissolved in 100% ethanol). After cooling to room temperature, 2 
ml petroleum ether and 1 ml water were added. The solution was vigorously vortexed 
and centrifuged at 2800 rpm for 15 min. The ether phase was separated and dried under 
a steam of nitrogen. A 1:1 mixture -N,O-Bis(trimethylsilyl)trifluoroacetamide and 
Pyridine was added to the test tube, transferred to GC vials and heated at 75°C for 20 
min. One microliter of the sample was injected into the GC (Agilent 6890 GC G2579A 
system; Palo Alto, CA) equipped with Agilent Column J&W 122-5711, DB5ht, and flame 
ionization detector (FID). An Agilent 5973 network mass selective detector was used to 
identify target peaks. The GC program was as follows: injector: 1 μl at 10:1 split, 360°C; 
detector: FID, 280°C; oven: 150°C (5 min) to 280°C at 8°C/min; carrier: helium, 1.0 
ml/min. Additional serum analysis was performed by FPLC fractionation using a 
Superose 6 HR10/30 column to separate lipoprotein fractions. Total cholesterol content 
in FPLC fractions was determined by colorimetric-enzymatic assays. Hepatic lipids were 
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determined by colorimetric assay following Folch extraction. Approximately 100 mg of 
liver was homogenized using dounce pestle. The homogenate was placed in 1 ml 
MBST/OG for 30 min in ice. Lipids were extracted in 2:1 CHCl3: MeOH at room 
temperature. The chloroform phase was dried under a stream of N2, solubilized in 1 
volume of Triton X-100/CHCl3, dried and resolubilized in 2 volumes of water. The 
measured values were normalized to the sample weight. 
 
Fecal neutral sterol analysis: Total feces from the 72 hr period, following infection (Day 
0), was collected, dried at 37°C, weighed and ground to powder. An aliquot of 0.125 g 
feces was placed into a glass tube with 1.25 ml ethanol and 0.25 ml 10 N NaOH. Lipids 
were saponified at 72°C in a water bath for 2 hrs and extracted (water, ethanol and 
petroleum ether, 1:1:1 v: v: v). 5α-cholestane (0.150 mg) was used as internal standard. 
Following extraction, the organic phase was dried under a steam of N2, and solubilized 
in hexane. The amount of neutral sterols (cholesterol, coprostanol and cholestanol) was 
quantified by GC-MS/FID. 
 
Membrane proteins and qRT-PCR analysis: The preparations of membrane proteins, 
SDS-PAGE and immunoblotting were conducted as previously described in Chapter 2. 
Total RNAs were extracted from liver followed by cDNA synthesis using the same 
procedures as in Chapter 2. To determine relative abundance, quantitative RT-PCR was 
conducted using SYBR Green as detector on Applied Biosystem 7900 HT fast-Real Time 
PCR System (Carlsbad, CA). Oligonucleotides used for qRT-PCR are listed in Table 3.1 or 
as reported in Chapter 2. 
 
Statistical analysis: Data are expressed as means ± SD. Data were analyzed by 1 way 
ANOVA. Post-hoc comparisons were conducted with a Dunnett’s Multiple Comparison 
test with obese control (Con) mice serving as the control. Differences were considered 
significant at p < 0.05.  
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TABLE 3.1:  Oligonucleotides used for quantitative RT-PCR 
Target Forward Reverse 
SREBP-2 GCGTTCTGGAGACCATGGA ACAAAGTTGCTCTGAAAACAAATCA 
HMGR CTTGTGGAATGCCTTGTGATTG AGCCGAAGCAGCACATGAT 
HMGS GCCGTGAACTGGGTCGAA GCATATATAGCAATGTCTCCTGCAA 
LDLR AGGCTGTGGGCTCCATAGG TGCGGTCCAGGGTCATCT 
LRP1 TCTCGTCCGTGCTGGCCAGG GGCTGCTGATGGCTCCCGAC 
SR-BI TCCCCATGAACTGTTCTGTGAA TGCCCGATGCCCTTGA 
VLDLR ACCTGTTCCTGTCCCAATGG TCACTGTAAGTCACAGGAGTTGAAGTAC 
NPC1L1 TGGACTGGAAGGACCATTTCC GCGCCCCGTAGTCAGCTAT 
FXR TGAGAACCCACAGCATTTCG GCGTGGTGATGGTTGAATGTC 
LRH-1 TGGGAAGGAAGGGACAATCTT CGAGACTCAGGAGGTTGTTGAA 
Cyp7a1 GCTGTCTGGGTCACGGAAGG AAGTGAATAGGGACGCCCGC 
Cyp8b1 GCCTTCAAGTATGATCGGTTCCT GATCTTCTTGCCCGACTTGTAGA 
Apo-A1 CTCCTCCTTGGGCCAACA TGACTAACGGTTGAACCCAGAGT 
ABCA1 CGTTTCCGGGAAGTGTCCTA GCTAGAGATGACAAGGAGGATGGA 
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RESULTS 
 
To restore biliary cholesterol elimination in obese (db/db) mice, I utilized adenoviral 
vectors encoding ABCG5 and ABCG8. Previous reports from liver-specific ABCG5/G8 
transgenic mice suggest that a significant portion of biliary cholesterol is reabsorbed and 
mitigates the efficacy of enhanced hepatic ABCG5/G8 activity [240]. Therefore, I 
expressed recombinant ABCG5/G8 in the presence and absence of the cholesterol 
absorption inhibitor, EZ. As an additional control, lean mice were maintained on 
standard chow and treated with the control virus. On the day of infection, mice were 
placed in clean cages and injected with either control adenovirus (Con) or a cocktail of 
adenoviruses encoding ABCG5 and ABCG8 (G5G8). Three days after adenoviral delivery, 
mice were killed and feces and tissues collected.  
 
Recombinant proteins were detected in pooled hepatic membrane preparations from 
G5G8 infected mice by immunoblot analysis (Figure 3.1A). Both the immature, reticular 
forms and mature, post-Golgi forms of G5 and G8 were present. Although there appears 
to be less ABCG5 and ABCG8 expressed in the EZ treated group, densitometric analysis 
of the individual samples and qRT-PCR of mRNAs for ABCG5 and ABCG8 indicated no 
statistical differences between these two groups (Figure 3.2). In addition, ABCG5/G8 
increased biliary cholesterol concentrations in obese (db/db) mice by 7.3 (Chow) and 9.3 
(EZ) fold compared to obese controls, suggesting that the level of ABCG5/G8 expression 
was functionally similar (Figure 3.1B).  
 
Although there is controversy in the literature, SR-BI levels are thought to be lower in 
leptin deficient mice and may contribute to the accumulation of large HDLs and reduced 
biliary cholesterol excretion. Therefore, hepatic levels of SR-BI were determined. In this 
cohort we did not observe differences in SR-BI between lean and db/db mice. 
Surprisingly, there was modest, but significant reduction in SR-BI in ABCG5/G8 
expressing mice (Figure 3.3A, B). 
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FIGURE 3.1. Protein expression and biliary cholesterol concentrations in lean and 
obese mice infected with control adenovirus (Con) or ABCG5 and ABCG8 (G5G8) in the 
presence and absence of ezetimibe (EZ). A) Immunoblotting analysis for ABCG5, ABCG8 
and SR-BI. Asterisk (*) denotes detection of a non-specific signal which overlaps with the 
lower molecular band weight of G5. B) Cholesterol concentrations in bile (mM). *** 
p<0.001. 
 
 
In a second cohort of db/db mice examined at 16 weeks of age significant reductions in 
both SR-BI protein and mRNA compared to their lean littermates was observed (Figure 
3.3C-E). Total plasma cholesterol and the FPLC profiles in these independent cohorts of 
db/db mice were virtually identical (Figure 3.5A, B, 3.3F, G). This indicates that while 
hepatic SR-BI levels may be reduced in db/db or ob/ob mice of different ages, the 
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dyslipidemic phenotype characteristic of these strains is not dependent upon a 
reduction in the abundance of SR-BI protein.  
 
 
 
 
Figure 3.2. Quantitative RT-PCR and densitometric analysis of ABCG5 and ABCG8 from 
liver in lean and obese mice infected with control adenovirus (Con) or ABCG5 and 
ABCG8 (G5G8) in the presence and absence of ezetimibe (EZ). The relative abundance 
of A) ABCG5 and B) ABCG8 were evaluated upon hepatic mRNA isolation by qRT-PCR. 
Membrane preparations for ABCG5 and ABCG8 were analyzed individually and also 
blotted for the loading control CNX. Relative abundance of C) ABCG5 and D) ABCG8 
protein was determined by densitometry. * p<0.05. 
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Figure 3.3. SR-BI protein and mRNAs in lean and obese (db/db) mice at 32 (A,B) and 16 
(C-G) weeks of age. Densitometric (A, D) and qRT-PCR analysis (B, E) of SR-BI from liver. 
Total and FPLC fractionated plasma cholesterol levels (F,G) were also determined. 
Samples were prepared and analyzed as described in methods.  * p<0.05, ** p<0.01, 
***p<0.001.  
 
 
As previously reported, FNS were lower in db/db mice compared to lean controls (Figure 
3.4 A). Hepatic ABCG5/G8 expression tended to increase FNS, but this difference failed 
to reach statistical significance. The inclusion of EZ in the diet increased FNS by 4.6 fold, 
but there was no further elevation in FNS in mice treated with both EZ and ABCG5/G8. 
Mice deficient in NPC1L1 exhibit an unexplained reduction in total stool output as well 
as alterations in the cholesterol to coprostanol ratio [243]. The inhibition of NPC1L1 with 
EZ also reduces stool output in obese (db/db) mice (Figure 3.4 B). Because the reduction 
in FNS in obese controls comes predominately at the expense of cholesterol, there is a 
dramatic decreased in the cholesterol to coprostanol ratio in db/db compared to lean 
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controls (Figure 3.4 C). The apparent increase in this ratio following EZ treatment alone 
failed to reach statistical significance. However, a 2 way ANOVA of the data from only 
db/db mice revealed an overall effect of EZ.  
 
 
 
 
FIGURE 3.4. Sterol balance in lean and obese mice infected with control adenovirus 
(Con) or ABCG5 and ABCG8 (G5G8) virus in the presence and absence of EZ. A) Total 
FNS output over 3 days following viral administration. B) Total stool output (dry weight) 
over 72 hrs. C) Ratio of fecal cholesterol to coprostanol.  * p<0.05, ** p<0.01, *** 
p<0.001.  
 
63 
 
Total serum cholesterol levels were elevated in obese (db/db) mice, but were 
unaffected by ABCG5/G8 expression or the inclusion of EZ in the diet (Figure 3.5 A). In 
the presence of EZ, hepatic expression of ABCG5/G8 reduced serum cholesterol, but 
failed to fully normalize total cholesterol to levels observed in lean controls. Serum from 
mice within each of the five groups was subjected to FPLC analysis (Figure 3.5 B). The 
reduction in plasma cholesterol in mice treated with ABCG5/G8 and EZ occurred in both 
the HDL and LDL/HDL1 fractions. Treatment with ABCG5/G8 or EZ alone had no effect on 
the FPLC profile of obese mice (not shown).  
 
The inability of hepatic ABCG5/G8 to lower plasma cholesterol in the absence of EZ 
suggests the increase in biliary cholesterol excretion was offset by reabsorption. 
Increasing dietary cholesterol modulates intestinal expression of genes involved in 
cholesterol absorption and synthesis [137]. Quantitative RT-PCR was used to determine 
if adenoviral G5G8 promoted a sufficient increase in intestinal cholesterol delivery to 
modulate expression in these pathways (Table 3.2.). Neither ABCG5/G8 expression nor 
the inclusion of EZ in the diet had an effect on intestinal levels of NPC1L1, ABCA1 and 
many other gene products involved in intestinal cholesterol absorption or synthesis. 
However, there was a significant reduction in HMGS in mice infected with ABCG5/G8 in 
the presence and absence of EZ. Intestinal lipid content was also measured (Table 3.3). 
While db/db mice have elevated intestinal lipids, compared to lean controls, the 
expression of ABCG5/G8 alone did not result in an accumulation of cholesterol. 
However, there was an increase in intestinal lipids in the presence of EZ. These data 
suggest that the increase in biliary cholesterol concentrations following ABCG5/G8 
expression had little impact on intestinal cholesterol delivery, but do not exclude a role 
for cholesterol reabsorption and intestinally derived lipoproteins in limiting the 
effectiveness of ABCG5/G8 expression in cholesterol lowering.  
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FIGURE 3.5. Serum cholesterol and lipoprotein profiles in lean and db/db mice 
infected with control adenovirus (Con) or ABCG5/G8 in the presence and absence of 
EZ. A) Total serum cholesterol levels in lean and db/db mice. * p<0.05, *** p<0.001. B) 
Relative cholesterol content in FPLC fractionated serum in individual samples and 
expressed as the average in each group.  Lean (Con, ▲) and obese (Con, ●) mice were 
infected with control virus and mice treated with both ABCG5/G8 and EZ (G5G8/EZ, ○). 
 
 
In order to determine the source of biliary cholesterol in ABCG5/G8 infected animals I 
measured hepatic lipids and gene expression. Not surprisingly, hepatic triglycerides and 
phospholipids were elevated in db/db mice, but there was no accumulation of hepatic 
cholesterol and no decrease following ABCG5/G8 expression in the presence or absence 
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of EZ (Table 3.2). Hepatic G5G8 expression increased HMG-CoA reductase (HMGCR) and 
synthase (HMGCS) mRNA levels in db/db mice in the presence or absence of EZ (p < 
0.05), suggesting up-regulation of cholesterol synthesis (Figure 3.6). VLDLR, LDLR and 
LRP1 mRNAs were not affected by G5G8 expression and increased biliary cholesterol 
secretion. Additional genes involved in bile acid metabolism and HDL biogenesis were 
also unaffected (Table 3.4). These data indicate that the increase of ABCG5/G8 activity 
and mobilization of cholesterol was detected by hepatocytes, but rather than promoting 
uptake of plasma lipoproteins, the net loss of cholesterol to bile was offset by an 
increase in synthesis. 
 
 
TABLE 3.2:  Intestinal gene expression (mRNA) in lean and obese mice following 
infection with ABCG5/G8 in the presence and absence of ezetimibe (EZ) 
Phenotype lean obese 
Diet chow EZ 
Virus control G5G8 control G5G8 
ABCG5 0.9±0.1 1.0±0.1 1.4±0.3 0.8±0.4 1.3±0.3 
ABCG8 1.0±0.1 1.0±0.1 1.2±0.2 0.8±0.2 1.3±0.3 
ABCA1 0.7±0.1 1.0±0.6 0.9±0.2 0.8±0.4 1.0±0.3 
LXRα 0.9±0.1 1.0±0.2 0.7±0.2 0.7±0.3 0.8±0.3 
SREBP2 1.6±0.3 1.0±0.4 0.6±0.2 0.8±0.4 0.6±0.2 
HMGCR 2.7±0.7a 1.0±0.7 1.0±0.3 1.2±0.4 1.1±0.5 
HMGCS 1.0±0.3 1.0±0.8 0.3±0.1a 0.5±0.1 0.3±0.1a 
NPC1L1 1.0±0.1 1.0±0.1 0.7±0.2 0.7±0.1 0.9±0.3 
SR-BI 1.3±0.2 1.0±0.1 1.1±0.2 1.4±0.5 0.1±0.3 
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TABLE 3.3:  Hepatic and intestinal lipids in lean and obese mice following infection 
with G5G8 in the presence and absence of ezetimibe (EZ) 
 
 
TABLE 3.4:  Hepatic expression of genes (mRNA) involved in HDL biogenesis and bile 
acid homeostasis 
Phenotypes obese 
Diet chow EZ 
virus control G5G8 control G5G8 
ABCA1 1.0±0.3 1.6±0.2 1.6±0.1 1.0±0.3 
Apo-A1 1.0±0.4 0.9±0.2 0.7±0.4 0.8±0.4 
LXRα 1.0±0.1 1.2±0.2 0.9±0.2 1.0±0.1 
FXR 1.0±0.2 0.8±0.1 1.0±0.3 1.0±0.2 
LRH-1 1.0±0.5 1.4±0.1 1.5±0.3 1.0±0.5 
Cyp7A1 1.0±0.1 1.1±0.8 0.7±0.4 1.1±0.8 
Cyp8b1 1.0±0.3 0.5±0.5 0.8±0.6 0.6±0.3 
Phenotype lean obese 
Diet chow EZ 
Virus control G5G8 control G5G8 
Intestine (mg/g) 
     
TC 0.56±0.1 1.25±0.5 1.2±0.6 1.6±0.2 2.83±1.2a 
TG 3.78±0.2 7.53±2.9 7.03±1.5 9.22±2.7 14.79±4.2a 
PL 6.22±2.0 8.74±0.6 8.94±3.4 14.3±1.8 16.8±1.8a 
Liver (mg/g) 
     
TC 1.88±0.2 2.04±0.3 2.63±0.2 1.8±0.4 1.93±0.7 
TG 5.22±0.4a 17.3±2.7 21.03±0.9 21.3±1.6 19.62±2.3 
PL 4.1±0.4a 12.5±1.4 15.35±0.4 11.1±1.8 12.86±2.2 
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FIGURE 3.6. Hepatic expression of genes in lean and obese mice infected with control 
adenovirus (Con) or G5G8 in the presence and absence of EZ. A) Relative abundance of 
hepatic mRNAs of genes involved in cholesterol biosynthesis: SREBP-2, HMGCR, HMGCS. 
B) Relative abundance of hepatic mRNAs of genes involved in liver cholesterol uptake: 
LDLR, LRP-1, VLDLR. Values represent mean ± SD of data from three animals in each 
group. * p<0.05.   
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DISCUSSION 
 
Mice lacking functional leptin or its receptor have decreased levels of hepatic 
ABCG5/G8, reduced biliary cholesterol excretion and increased HDL cholesterol 
associated with a delayed clearance of these particles. In the present study, I tested the 
hypothesis that accelerating biliary cholesterol excretion by adenoviral expression of 
ABCG/5G8 could correct dyslipidemia in db/db mice. These results demonstrate that 
accelerating biliary cholesterol excretion can reduce both HDL and large HDL1 particles 
characteristic of db/db mice when cholesterol absorption is inhibited with EZ. However, 
the combination of these treatments failed to fully correct dyslipidemia. This may be 
due to the acute nature of the experiment; perhaps sustained expression of ABCG5/G8 
in the presence of EZ could fully restore the lipoprotein profile in db/db mice. 
 
The role of enhanced ABCG5/G8 activity in opposing plasma accumulation of dietary 
cholesterol in ApoB containing lipoproteins is well established [244]. In the present 
study, hepatic ABCG5/G8 partially corrected a dyslipidemia characterized by increased 
cholesterol in ApoA containing lipoproteins in mice maintained on low cholesterol diets. 
The classical view of RCT presumes that cholesterol elimination requires delivery of 
cholesterol from peripheral tissues to the liver. However, an emerging body of literature 
supports a significant role for transintestinal excretion of cholesterol and recent studies 
have produced conflicting results on the necessity of biliary cholesterol excretion on 
macrophage RCT [172, 174, 245-247]. The relative contribution of this alternative 
pathway on overall RCT and in opposing the accumulation of endogenously synthesized 
cholesterol in plasma is not known. 
 
The data are consistent with previous reports that EZ promotes transintestinal 
elimination of cholesterol. Despite a five-fold increase in fecal sterol loss, EZ treatment 
alone failed to lower serum cholesterol in db/db mice. My analysis of hepatic and 
intestinal gene expression as well as lipids in these tissues and bile did not reveal the 
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source for increased fecal sterols in EZ treated mice. Similarly, biliary cholesterol 
excretion was increased almost eight-fold in ABCG5/G8 infected mice in the absence of 
EZ without a reduction in plasma cholesterol. Clearly, this level of excretion reduced the 
regulatory pool of cholesterol in hepatocytes which unregulated the expression of 
cholesterol synthetic genes. However, I saw no increase in hepatic SR-BI or LDLR mRNAs. 
This observation suggests that biliary cholesterol excretion and hepatic uptake of HDL 
are functionally uncoupled. Whether this is a common feature or unique to db/db mice 
it is not known. 
 
Although leptin has been shown to increase SR-BI levels in ob/ob liver, there are 
conflicting reports on whether the abundance of the HDL receptor is reduced [232, 241]. 
Unfortunately, our study does nothing to resolve this issue. In independent cohorts of 
db/db mice I obtained different results for SR-BI levels in the liver. Housing, diet, light: 
dark cycle and other conditions of animal husbandry were not different between these 
two groups. Although these mice were of different ages, this explanation is unsatisfying. 
What can be said is that there is no correlation between HDL levels in plasma and 
alterations in SR-BI abundance in db/db mice. It is also important to note that I did not 
determine HDL clearance rates or other measures of SR-BI function in the studies.  
 
In conclusion, effective cholesterol lowering via enhanced biliary excretion was entirely 
dependent on EZ treatment. Put another way, reducing plasma cholesterol by inhibition 
of cholesterol absorption was entirely dependent on enhanced biliary cholesterol 
excretion. These observations reveal the requirement for a cooperative relationship 
between the liver and intestine for reducing plasma cholesterol in db/db mice. 
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Chapter 4:  PLANT STEROLS INFLUENCE ABC TRANSPORTER EXPRESSION, 
CHOLESTEROL EFFLUX AND INFLAMMATORY CYTOKINE SECRETION IN MACROPHAGE 
FOAM CELLS 
 
 
INTRODUCTION 
 
A number of functional foods contain added phytosterols, a mixture of commonly 
consumed non-cholesterol sterols (sitosterol, campesterol and stigmasterol) found in 
the oils of the seeds, beans, and legumes of the plants from which they are extracted 
[18]. When supplied at a dose of 2-4 g per day, phytosterol-esters and their fully 
hydrogenated stanol-ester derivatives reduce LDL cholesterol by approximately 10%, 
even when added to statin therapy [248-250]. However, patients consuming 
phytosterols in the form of supplements and functional foods have increased 
phytosterols in plasma and tissues [18, 248-251]. It is not known if this increase in 
plasma phytosterols is required for their cholesterol lowering effect, nor is it known if 
this level of accumulation confers cardiovascular risk or benefit. 
 
There is considerable controversy in the literature concerning the association between 
plasma levels of plant sterols and the incidence of cardiovascular disease [248, 250, 
252]. As with the clinical data, studies in mouse models of atherosclerosis have 
generated mixed results. Phytosterol supplementation in mice lacking one copy of the 
LDL receptor resulted in a reduction in both plasma cholesterol and vascular lesion area 
[22]. However, a more recent study in ApoE deficient mice showed that phytosterol 
supplementation impaired endothelial function, increased lesion size following cerebral 
artery occlusion, and increased atherosclerotic lesion area compared to mice treated 
with the cholesterol absorption inhibitor, EZ [251]. In fact, patients that reported regular 
use of phytosterol supplements had the highest phytosterol concentrations in both 
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plasma and lesions [251]. However, no conclusions can be made concerning the role of 
phytosterols in disease progression. 
 
Studies addressing cardiovascular phenotypes in both humans and rodents have 
generally been limited to commercially available mixtures of phytosterols. However, it is 
clear from a variety of in vitro studies that individual phytosterols have distinct 
biological activities that include the modulation of signaling pathways and activation of 
cellular stress responses, growth arrest, and death mechanisms [253-255]. Many of 
these have implications for lipid metabolism, inflammation and the development of 
cardiovascular disease. The pro-apoptotic characteristics of sitosterol recognize this 
plant sterol as cytotoxic and chemotherapeutic-sensitizing agent to cancer cell lines 
[255, 256]. Stigmasterol and campesterol, but not sitosterol, interfere with SREBP 
processing and reduce the expression of genes in the cholesterol biosynthetic and 
uptake pathways in Y1 adrenal cells [257]. Independently of SREBP processing, 
stigmasterol is shown to be an LXR ligand that promotes the expression of ABCA1 and 
ABCG1, two transporters involved in the reverse cholesterol transport pathway that 
opposes cholesterol accumulation in tissues [257, 258]. Conversely, stigmasterol had no 
effect on LXR dependent gene expression, and antagonized FXR and PXR activity in 
hepatocytes [259]. Collectively, these observations indicate that the biological activity of 
phytosterols is both cell-type and sterol specific. 
 
Campesterol, sitosterol and stigmasterol individually have the potential to decrease 
apoB hepatic levels and retard the production of atherogenic lipoproteins in liver 
(HepG2) and intestinal (CaCo-2) cell lines [27]. Whereas stigmasterol has the ability to 
suppress hepatic HMGR and CYP7A1 activity, reduce cholesterol absorption and 
decrease hepatic cholesterol content when fed to rats, sitosterol accelerates cholesterol 
synthesis and induces cell death in mouse peritoneal macrophages [28-30].  
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Experimental Rationale 
There is inconsistency in the literature regarding the beneficial or deleterious effects of 
plant sterols. Although phytosterols accumulate in vascular lesions, the actions of 
phytosterols on macrophage function are poorly understood. Clearly, plant sterols 
confer LXR agonist activity or/and interfere with SREBP processing influencing 
cholesterol homeostasis. We hypothesized that individual phytosterols would 
differentially influence macrophage ABC transporter abundance, cholesterol efflux and 
inflammatory cytokine secretion. 
 
 
EXPERIMENTAL PROCEDURES 
 
Reagents and Buffers: Stigmasterol, 22(R)-dehydrocholesterol, and 5µ-cholestane were 
purchased from Steraloids (Newport, RI). Cholesterol, β-sitosterol, campesterol, 
brassicasterol, Phorbol 12-myristate 13-acetate (PMA) and 1α, 2α[3H ]-cholesterol were 
purchased from Sigma (St. Louis, MO). Sterols were solubilized in 100% ethanol at a final 
concentration of 5 mg/ml. RPMI 1640 medium, Fetal Bovine Serum (FBS), and L-
glutamine were purchased from Atlanta Biologicals (Lawrenceville, GA). 
Penicillin/Streptomycin was obtained from Invitrogen/Gibco (Carlsbad, CA). Human Apo 
A-I was purchased from Biodesign International (Saco, ME). Anti-ABCG1 antibody was 
purchased from GeneTex (San Antonio, TX). Anti-ABCA1 antibody was a kind gift from 
Mason Freeman (Harvard Medical School, Boston, MA). Quantitative real-time PCR, the 
preparation of membrane proteins, SDS-PAGE, and immunoblotting were conducted as 
described in CHAPTER 2. 
 
Animals and Cell Culture: All animal procedures were conducted in accordance with the 
University animal care and use committee. C57BL6/J male mice (Jackson Laboratories, 8-
10 weeks) were injected intraperitoneally with 2 ml of sterile 10% Brewer’s 
thioglycollate medium. Five days after injection, macrophages were collected by 
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peritoneal lavage using sterile phosphate-buffered saline (PBS). Mouse peritoneal 
macrophages (MPMs) were washed with PBS, recovered by centrifugation at 500 x g (10 
min, 22oC), suspended in Medium A (RPMI 1640 containing 10 mM HEPES buffer, 
gentamicin (50 µg/ml), streptomycin (100 µg/ml), penicillin (100 IU/ml), and sodium 
bicarbonate (2 g/L), 7.5% FBS). Cells (9 x 106) were plated in 10 cm dishes for 4 hours. 
Cells were washed once, fed Medium A and cultured for 24 hr prior to initiation of 
experiments. For treatment with sterols, cells were incubated in Medium B (RPMI 1640 
containing 10 mM HEPES buffer, gentamicin (50 µg/ml), streptomycin (100 µg/ml), 
penicillin (100 IU/ml), and sodium bicarbonate (2 g/L), 2 mg/ml fatty acid free BSA). 
Medium C consisted of Medium B supplemented with sodium compactin (5 µM) and 
mevalonate (50 µM). 
 
Human monocyte/macrophages (THP-1) were obtained from the American Type Culture 
Collection (ATCC) and maintained in Medium D (RPMI 1640 containing 10 mM HEPES 
buffer, gentamicin (50 µg/ml), streptomycin (100 µg/ml), penicillin (100 IU/ml), and 
sodium bicarbonate (2 g/L), 5% FBS) according to the suppliers instructions. For studies 
of THP-1 macrophages, monocytes were seeded at a density of 1.5 x 106 cells per well in 
6-well plates in Medium D containing 50 ng/ml phorbol myristate acetate (PMA) and 
allowed to differentiate into macrophages for 72 hrs. Following differentiation, the 
medium was removed, the cells were washed twice with Medium B, and treatments 
applied as in MPMs as indicated. 
 
Lipoproteins: Low density lipoprotein (LDL; d=1.020-1.063 g/ml) and HDL (d=1.063-1.21 
g/ml) were isolated as previously described and generously provided by Dr. Marcielle de 
Beer (Cardiovascular Research Center, University of Kentucky) [260]. Aggregated LDL 
(agLDL) preparation: isolated LDL (1 mg/ml protein) was aggregated by vortexing for 1 
min. To break large aggregates, the solution was sonicated for 10 min (70% duty cycle) 
on ice using a Branson Sonifier and passed through a 0.45 µm filter. Measurement of 
thiobarbituric acid-reactive substances (TBARS) was conducted to confirm the absence 
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of oxidation during the aggregation procedure. For the incorporation of phytosterols 
into agLDL, aggregation was conducted in the presence of the indicated sterol. 
Partitioning of exogenously added sterols into agLDL was confirmed using [3H]-
cholesterol and [3H]-sitosterol. Greater than 99% of labeled sterols were TCA 
precipitable under these conditions (not shown). 
 
Cholesterol Loading and Analysis: To measure cholesterol loading, macrophages were 
incubated for 48 hr at 37°C in Medium B alone, in the presence of the indicated sterols 
delivered in ethanol, or in 100 µg protein/ml agLDL containing the indicated sterols and 
their concentrations. Following extensive washing, total cellular lipids were extracted 
twice with 2 ml of hexane:isopropanol (3:2), dried under nitrogen gas and suspended in 
1 ml of 33% KOH (in ethanol) containing 5 µg of 5α-cholestane as an internal standard. 
Samples were saponified at 70oC for 2 h. Water (1 ml) and petroleum ether (2 ml) were 
added to each sample. Samples were vigorously vortexed for 2 min, centrifuged (2000 x 
g, 10min, and 22oC), and the organic phase collected, and dried under nitrogen gas. 
Sterols were derivatized using N,O-Bis(trimethylsilyl)trifluoroacetamide:pyridine (1:1) 
(Sigma) and assayed by gas chromatography-mass spectroscopy (GC-MS) as previously 
described [261]. Cell proteins were solublized in 1N NaOH overnight and total protein 
determined by BCA assay (Pierce). Total cellular sterol content was expressed as µg 
sterol per mg total cell protein after normalization to the internal standard. The limit of 
detection for sterols by GC-MS is 50 ng/mg total cell protein. 
 
Cholesterol Efflux: THP-1 and mouse peritoneal macrophages were loaded with agLDL 
(100 µg/ml protein) containing the indicated sterols and 1 µCi/ml [3H]-cholesterol for 24 
hours in Medium E (RPMI 1640 containing 10 mM HEPES buffer, gentamicin (50 µg/ml), 
streptomycin (100 µg/ml), penicillin (100 IU/ml), and 2 g/L sodium bicarbonate, 1% FBS). 
[3H]-cholesterol (10 µCi/mg LDL protein) was added to LDL prior to aggregation. Cells 
were washed and allowed to equilibrate in Medium F (RPMI 1640, 10 mM HEPES buffer, 
0.2 mg/ml fatty acid free BSA) for 1 hr. Cells were washed and cholesterol efflux was 
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determined in the presence or absence of Apo AI (30 µg/ml) or human HDL (100 µg/mL) 
in Medium B for 4 hr. [3H]-cholesterol present in the medium and cells was determined 
by liquid scintillation counting, normalized to total cell protein and percent efflux 
calculated. Percent efflux from cells incubated in medium containing neither acceptor 
was subtracted as background. 
 
Inflammatory Cytokine Measurement: Inflammatory cytokine production was 
measured in the supernatants of THP-1 macrophages cultured in medium (control), 
agLDL (100 µg/ml) prepared in the presence of carrier or the indicated sterol (10 µg/ml) 
for 48 hours. As a positive control for activation of macrophages, cells were incubated 
for 24 hr in the presence of IFNγ (20 ng/ml) followed by LPS (100 ng/ml). The culture 
media were collected and centrifuged to remove non-adherent cells. Cytometric Bead 
Array (CBA) Kits (BD Pharmingen, San Jose, CA) were utilized to simultaneously quantify 
the following cytokine concentrations: TNFα, interleukin (IL) -1β, IL-6, IL-8, IL-10 and IL-
12 as previously described [262, 263]. These cytokines, with the exception of IL-10, are 
indicative of the inflammatory function of macrophages produced at high levels through 
classical activation. Bead populations with distinct fluorescence intensities coated with 
capture antibodies specific for each cytokine were incubated with fluorochrome - 
conjugated detection antibodies along with 50 µl of a two-fold dilution of each sample 
for 3 hours at room temperature. Fluorescence intensities were assayed by flow 
cytometry and compare to a standard curve generated for each cytokine to determine 
the concentration in each sample. 
 
Statistical Analysis: Data were analyzed by one-way ANOVA to determine if there were 
differences among treatment groups. A post-hoc Dunnett's multiple comparison test 
was conducted to compare each treatment to the control.   
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RESULTS 
 
Previous reports indicate that the effects of phytosterols on LXR and SREBP-2 target 
genes are cell type dependent. To determine their effects in macrophages, I evaluated 
ABCA1 and LDLR protein abundance in elicited MPMs following treatment with 
individual non-cholesterol sterols differing at the 22 and 24 carbon positions within the 
cholesterol side chain (Figure 4.1).  
 
 
 
FIGURE 4.1. Effect of 22 and 24 substitution of the cholesterol side-chain on 
expression of ABCA1 and LDLR in MPMs. A) Immunoblot analysis for ABCA1 and LDLR 
levels from MPMs. B) Densitometric analysis of the signal intensities for ABCA1 and 
LDLR were normalized to the values obtained for Calnexin. Data represent the mean ± 
SD. (*) denote significant differences from control treated cells at p < 0.01.  
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Cells were harvested, cultured for 24 hr and incubated in the presence of serum free 
medium containing carrier (Control, ethanol) or medium supplemented with 50 µg/ml 
of the indicated sterol for 48 hr. Consistent with previous reports in Y1 adrenal cells, 
stigmasterol and 22(R)-dehydrocholesterol increased ABCA1 expression and decreased 
LDLR abundance whereas the remaining sterols had no effect. One potential explanation 
for the differences in responses among the sterols is their entry and accumulation in 
macrophages.  
 
The concentrations of phytosterols used in this and previous studies are substantially 
greater than what are typically observed in plasma of individuals consuming phytosterol 
supplements. To determine if phytosterols affected the expression of ABCA1 and LDLR 
at concentrations that are observed in vivo (4-20 μg/ml [30]), I conducted a time-course 
experiment using 10 μg/ml phytosterol (Figure 4.2A). Among the commonly consumed 
phytosterols, only stigmasterol increased expression of ABCA1 and decreased 
expression of LDLR. The effects of stigmasterol on ABCA1 and LDLR were discernable by 
4 hours and persisted up to 48 hours. However, LDLR expression decreased in control 
cells after 24 hours, suggesting that reductions over this period were unrelated to the 
presence of stigmasterol. This result also implies that the cellular content of cholesterol 
is dynamic over the 72 hr culture period and that the effects of stigmasterol may be 
dependent upon, or secondary to changes in endogenous cholesterol synthesis, a 
known source of LXR ligands [258]. To address this concern and to determine the 
minimal concentration of stigmasterol required to elicit changes in ABCA1 and LDLR 
abundance, a dose-response experiment was conducted in the presence of the HMGCR 
inhibitor, compactin (Figure 4.2B). The presence of compactin suppresses ABCA1 and 
upregulates LDLR. Therefore, 1 µg/ml 25-hydroxycholesterol (25-OH-C) was used as a 
positive control since it is known to be both an LXR agonist and a suppressor of SREBP 
processing. Stigmasterol treatment (0 to 50 µg/ml for 24 h) resulted in an increase in 
ABCA1 that was detectible at 1 µg/ml, increased substantially at 10 μg/ml, and 
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continued to increase, albeit to a lesser extent from 10 to 50 μg/ml. For LDLR, a modest 
suppression was observed at 0.5 μg/ml and further increases in stigmasterol resulted in 
complete suppression of immunoreactive LDL receptor. These results demonstrate that 
the effects of stigmasterol on LDLR and ABCA1 in macrophages are dose-dependent and 
not due to accumulation of cholesterol biosynthetic intermediates. 
 
 
 
FIGURE 4.2. Effect of time and concentration of stigmasterol on immunoreactive 
ABCA1 and LDLR in elicited MPMs. ABCA1, LDLR and Calnexin protein expression 
analyzed after A) Time-course experiment with MPMs cultured in Medium B containing 
stigmasterol (10 µg/ml) for up to 48h. B) Concentration dose dependent effect of 
stigmasterol on MPMs incubated in Medium C. 25-OH-C was used as a positive control 
for 24 hrs.   
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Next I determined if the effect of stigmasterol on ABCA1 abundance was associated with 
changes in mRNA levels for this and other LXR target genes (Figure 4.3). Each of the LXR 
target genes was increased by stigmasterol, but not sitosterol.  
 
 
 
FIGURE 4.3. Effect of stigmasterol on the expression of LXR (A) and SREBP1 (B), SREBP2 
(C) and selected target genes in MPMs. Macrophages were incubated in Medium C 
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(Control) or Medium C supplemented with LXR agonist, TO901317 (1 µM) was used as a 
positive control, sitosterol (10 µg/ml), stigmasterol (10 µg/ml), or 25-OH-C (1 µg/ml) for 
24 hrs. Total RNA was isolated and processed for quantitative RT-PCR. Data represent 
the mean ± SD. (*) denote significant differences from control treated cells at p < 0.01. 
 
 
Similarly, campesterol did not alter LXR target gene expression. We also evaluated 
expression of SREBPs and selected targets. Not surprisingly, SREBP-1c was also 
upregulated by stigmasterol as well as its downstream targets fatty acid synthase (FASN) 
and acetyl-CoA carboxylase (ACC1). However, stigmasterol had no effect on SREBP2 or 
its target genes, suggesting the mechanism by which stigmasterol suppresses LDLR 
protein is post-transcriptional, distinct from that of 25-OH-C, and independent of 
interference with SREBP processing. 
 
Although plant sterols may affect gene expression and cholesterol trafficking when 
added directly to the culture medium, macrophage foam cells acquire plant sterols from 
modified lipoproteins in vivo. Moreover, increased atherogenicity is suggested to occur 
when lipid stores are accumulated in the lysosomes and are less available for efflux from 
the macrophages compared to cytoplasmic occlusions [264]. Commonly used ox-LDL 
and acetylated LDL (ac-LDL) when incubated with MPMs accumulate cholesterol 
predominantly in cytoplasmic occlusions [265]. In addition, LDL aggregates are poorly 
processed by MPMs [266]. Therefore we selected THP-1 cells since these cells are an 
established model of macrophage foam cells that readily internalize and process agLDL 
in lysosomes [267]. First, I confirmed that the effects of individual phytosterols on ABC 
transporter expression would persist in lipid loaded cells and that they were not unique 
to MPMs. Following differentiation, THP-1 macrophages were cultured with medium 
supplemented with agLDL (Control) or agLDL prepared in the presence of the indicated 
sterol. As a positive control, cells were incubated in medium containing both agLDL and 
an LXR agonist (TO901317).   
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FIGURE 4.4. Effect of major phytosterols on expression of ABCA1 and ABCG1 and 
cholesterol efflux to ApoAI and HDL in agLDL loaded THP-1 macrophages. A) 
Immunoblotting analysis for levels of ABCA1 and ABCG1 after 48 hr incubation in Media 
E containing carrier (agLDL, 100 mg/g protein), T0901317 (10 μM) and designated 
sterols (10 μg/ml). B) Percent cholesterol efflux assay measured in a parallel 
experiment. [3H]-cholesterol (10 µCi/mg LDL protein) was added to LDL prior to 
aggregation. Data are the mean ± SD of three replicates. (*) denote significant 
differences (P< 0.05) compared to control cells. 
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As an additional control, agLDL was prepared in the presence of cholesterol to maintain 
equality of total added sterols. Following 48 hr of treatment, membrane proteins were 
prepared and analyzed by SDS-PAGE and immunoblotting (Figure 4.4 A). Incubation of 
THP-1 macrophages with agLDL in the absence of additional sterols increases ABCA1 and 
suppresses LDLR below the limits of detection (not shown). The addition of the LXR 
agonist further increased ABCA1 protein in agLDL loaded macrophages. ABCG1 was also 
increased in THP-1 loaded macrophages, the measurements of which proved difficult in 
mouse macrophages using commercially available antibodies. The incorporation of 
cholesterol, sitosterol and campesterol in agLDL had no effect on ABCA1 or ABCG1 
abundance. Consistent with mRNA data in MPMs, the inclusion of stigmasterol in agLDL 
increased both transporters in human macrophages, whereas other phytosterols had no 
effect. 
 
 
TABLE 4.1:  Cellular sterol content (µg/mg total cell protein) following incubation with 
agLDL prepared in the presence (+) of the indicated sterol 
Sterol 
Control 
agLDL + 
Carrier Cholesterol Stigmasterol Sitosterol Campesterol 
Cholesterol 
7.89 
± 0.74 
42.96 
± 5.74 
47.36 
± 6.52 
49.00 
± 6.18 
45.21 
± 10.18 
44.68 
± 1.92 
Stigmasterol    
6.41 
± 2.43 
  
Sitosterol     
5.28 
± 1.22 
 
Campesterol      
14.16 
± 1.01 
Total Sterols 
7.89 
± 1.04 
42.96 
± 5.74 
47.36 
± 6.52 
55.41 
± 5.14 
50.49 
± 3.65 
58.84 
± 3.37 
 
Values represent means ±SD. Empty cells indicate that levels were below the limits of 
detection by GC-MS (50 ng/mg total cell protein). 
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Cellular sterol content was determined before and after incubation with agLDL (Table 
4.1). Lipids were extracted and analyzed by GC-MS. Incubation of THP-1 macrophages 
with agLDL resulted in a 5-6 fold increase in total cellular sterol content. The addition of 
phytosterols collectively and individually had no effect on the extent of cholesterol 
accumulation or total cellular sterol content when compared to the cholesterol control, 
indicating that changes in ABC transporter expression are not merely a function of total 
cholesterol or sterol content of THP-1 macrophages. 
 
Next I determined if phytosterols altered efflux of cholesterol from agLDL loaded THP-1 
macrophages to apoA-I and HDL (Figure 4.4 B). THP-1 monocytes were differentiated 
into macrophages and incubated with agLDL prepared in the presence of [3H]-
cholesterol and the indicated sterol for 48 hours (100 μg/ml LDL, 10 μg/ml sterol, 1 
μCi/ml [3H]-cholesterol). Following the loading phase, the cells were washed and 
allowed to equilibrate in serum free medium for 1 hr. The equilibration medium was 
removed, the cells were washed and the medium replaced in Medium B containing 
apoA-I (30 μg/ml) or HDL (100 μg/ml) for 4hr. Relative to control cells, in which no 
additional sterols were added to the LDL aggregates, TO901317 enhanced efflux of [3H]-
cholesterol to both apoA-I and HDL. Sitosterol had no effect on efflux to either acceptor, 
although there was a tendency for a decrease to HDL. The presence of stigmasterol 
increased efflux to apoA-I by 25% and tended to increase efflux to HDL. Campesterol 
resulted in a modest, but significant decrease in efflux to HDL, but did not alter efflux to 
apoA-I. These results indicate that the effects of individual phytosterols on ABC 
transporter expression and cholesterol efflux are directly correlated in human cultured 
macrophages.   
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Figure 4.5. Sterol loading of THP-1 cells induces the synthesis and secretion of TNFα, 
IL-6 and IL-1β. THP-1 macrophages were incubated in medium (control), agLDL (carrier) 
or agLDL with the indicated sterol (10 µg/ml) for 48 h. As a positive control for activation 
of macrophages, cells were incubated for 24 hr in the presence of IFNγ ng/ml) followed 
by LPS (100 ng/ml). The amount of A) TNFα, B) IL-6 and C) IL-1β released to the media 
were analyzed by CBA assay. Data are the mean ± SEM of six replicates. ** p < 0.01 vs. 
untreated control, * p < 0.05 vs. untreated control, † p < 0.05 vs. AgLDL + carrier.  
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Beyond the accumulation of lipid, macrophages contribute to the inflammatory state of 
the atherosclerotic lesion. To determine if phytosterols alter the inflammatory response 
to agLDL loading, I evaluated the secretion of inflammatory cytokines in the culture 
medium using a commercially available cytometric bead assay (CBA) inflammation panel 
(Figure 4.5). First, I used pretreatment with interferon (IFN)-γ followed by 
lipopolysaccharide (LPS) as a control for classical activation of macrophages. Following 
pretreatment with IFN-γ, LPS dramatically increased the secretion of TNFα, IL-6 and IL-
1β. Compared to untreated cells, incubation with agLDL increased the expression of 
each of these proinflammatory cytokines. The effect of phytosterols on the response to 
agLDL loading was assessed by comparing the levels of secreted cytokines to cells 
treated with agLDL prepared in the presence of the carrier (ethanol). The presence of 
stigmasterol decreased agLDL-induced secretion of TNFα, IL-6 and IL-1β. The presence 
of sitosterol increased the secretion of TNFα and IL-1β, but not IL-6. Campesterol had no 
effect on the inflammatory response to agLDL. Levels of IL-8 were unaffected by 
treatments. IL-10 and IL12p70 were below the limits of detection in our assay (not 
shown). 
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DISCUSSION 
 
These studies report that stigmasterol increases expression of ABCA1 and ABCG1, 
enhances cholesterol efflux, and decreases the inflammatory response to uptake of 
modified lipoproteins in multiple models of macrophage foam cells. Conversely, 
sitosterol exacerbated the inflammatory response of agLDL loading and tended to 
decrease cholesterol efflux. Although campesterol had no effect on the abundance of 
ABC transporters or secretion of cytokines, it had a modest inhibitory effect on 
cholesterol efflux from agLDL loaded macrophages to HDL. 
 
The increase in efflux to apoA-I and HDL in the presence of stigmasterol is presumably 
mediated by the increase in ABCA1 and ABCG1 protein, respectively. However, a role for 
other sterol transporting proteins such as SR-BI, CD36 and ABCG4 cannot be excluded. 
Further complicating matters is the fact that LXR agonists have been shown to enhance 
efflux of cholesterol by promoting the transport of cholesterol to the cell surface in 
human macrophages [268]. Given that stigmasterol interacts with at least two 
independent sterol sensing mechanisms in other cell types, the precise mechanism(s) by 
which stigmasterol enhances cholesterol efflux to apoA-I and HDL in macrophages 
remains difficult to definitively establish. Similarly, the mechanism for suppression of 
inflammatory cytokine secretion remains unknown, but is likely related to activation of 
LXR signaling based on the increase in LXR target genes by this sterol and emerging role 
of this nuclear hormone receptor in the suppression of inflammation [269].  
 
The suppression of LDLR by stigmasterol appears to be independent of disruptions in 
SREBP2 processing since target genes for this transcription factor are unaffected by this 
phytosterol. It is tempting to speculate that the mechanism is also LXR dependent based 
on recent reports of LXR-mediated LDLR degradation [104]. However, I did not pursue 
this effect of stigmasterol in macrophage foam cells since lipid loading in the absence of 
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stigmasterol or the synthetic LXR ligand is sufficient to suppress LDLR levels below the 
limits of detection.  
 
In general terms, the effects of sitosterol were opposite of stigmasterol. Sitosterol 
increased the inflammatory response of agLDL loaded macrophages and tended to 
reduce cholesterol efflux. However, sitosterol had no effect on immunoreactive levels of 
ABC transporters or mRNA levels of any of the transcripts examined. Previous reports in 
macrophages and other cell types indicate that sitosterol inhibits cell growth, activates 
components of the integrated stress response and at sufficient concentrations is toxic to 
cells [254, 255]. I did not observe cytotoxicity with sitosterol treatment in these studies, 
but it is important to note that it did not quantify direct measures of cellular stress since 
these effects were beyond the scope of our study. 
 
These studies add to a growing body of literature demonstrating that individual 
phytosterols affect a number of signaling, trafficking, and enzymatic mechanisms with 
implications in the development and progression of cardiovascular disease. The relative 
abundance of stigmasterol in commercially available phytosterol supplements and 
functional foods compounded with its limited absorption make it unlikely that the levels 
of this individual phytosterol accumulate in sufficient quantities to have a significant 
positive impact on the reverse cholesterol transport or inflammatory pathways within 
macrophages. However, supplying stigmasterol as the sole source of phytosterol in the 
diet increased its levels to 20 μg/ml in serum and reduced cholesterol absorption, 
plasma cholesterol and hepatic HMGCR activity, suggesting that the beneficial effects of 
this phytosterol are achievable [30]. 
 
A critical question with respect to the use of phytosterols as supplements and within 
functional foods is whether the benefits of cholesterol lowering are greater than 
potential risk associated with the accumulation of plant sterols in plasma and tissues. It 
is important to note that humans consume significant amounts of phytosterols 
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depending on their diet and phytosterol supplements are generally regarded as safe. 
However, cholesterol lowering therapies persist for decades. Increasing phytosterol 
consumption to levels sufficient for cholesterol lowering, particularly in patients that 
harbor polymorphisms in ABCG5/ABCG8, may limit cardiovascular benefit depending on 
sterol composition. On the other hand, added benefit may be achievable through the 
use of supplements enriched in stigmasterol or other 22-dehydrosterols. Additional 
studies of individual phytosterols are required to determine if sterol composition can be 
optimized to achieve added cardiovascular benefit beyond cholesterol lowering. 
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Chapter 5:  SUMMARY OF RESEARCH 
 
The clinical and epidemiological importance of CVD related to vascular lesion 
development has been growing rapidly in the recent decades. Obesity, insulin resistance 
and hypercholesterolemia are frequent metabolic derangements found in patients with 
progressing atherosclerosis, and are often linked to impaired reverse cholesterol 
transport (RCT). RCT is an atheroprotective process whereby ABC cholesterol 
transporters (ABCA1, ABCG1 and ABCG5/G8) play a crucial role in initiating the 
movement of cholesterol from peripheral tissues and vascular lesion macrophages to 
the liver as well as promoting hepatic cholesterol excretion out of the body. The major 
findings of these studies are the post-transcriptional regulation of the ABCG5/G8 
complex and its cooperate role in the liver and intestine in the process of maintaining 
cholesterol homeostasis. My data demonstrated that a defect in the leptin axis is 
associated with reductions in ABCG5/G8 protein. Leptin replacement and caloric 
restriction restored ABCG5/G8 abundance which were further associated with increased 
biliary cholesterol excretion and corrected hypercholesterolemia in ob/ob mice. 
Although TUDCA treatment and liver specific ABCG5/G8 adenoviral replacement 
increased ABCG5/G8 protein expression and accelerated biliary cholesterol secretion, it 
failed to correct dyslipidemia in obese db/db mice. Further, adenoviral ABCG5/G8 
ameliorated high cholesterol levels only when cholesterol reabsorption was inhibited, 
underscoring the collaborative role between hepatic and intestinal ABCG5/G8. In the 
last chapter, my in vitro studies reported that phytosterols influence the initial step of 
RCT and had diverse effects on cholesterol efflux and pro-inflammatory response in 
macrophage foam cells.  
 
Beyond the fact that ABCG5 and ABCG8 are N-linked glycoproteins which reside in the 
ER as monomers and require CNX or CRT for proper protein folding for heterodimer 
complex formation and trafficking to the cell surface, little is known about the post-
transcriptional regulation of these cholesterol transporters. To gain insight into the 
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process, series of in vivo experiments were conducted in leptin-axis defective mice 
(db/db and ob/ob). These strains exhibit pronounced obesity, dyslipidemia and reduced 
biliary cholesterol secretion. In fact, the mice remain resistant to gallstone formation 
while maintained on high cholesterol and cholate diet, suggesting an effect of leptin 
deficiency on hepatobiliary regulation [214]. Hepatic immunoblot analysis from db/db 
and ob/ob mice revealed that impaired cholesterol excretion into the bile is associated 
with a reduction in ABCG5/G8 protein. This decrease did not correlate with a reduction 
in messenger RNA of the sterol transporters. Cell culture studies indicated that the half-
life of the immature forms of ABCG5 and ABCG8 are significantly shorter compared to 
the mature forms, but the two forms of the proteins are present in similar amount [74]. 
My animal studies revealed that there was a difference between the processed and 
unprocessed form of ABCG5 and ABCG8 in wild type control mice, suggesting efficient 
assembly of the complex in the ER and/or prolonged stability of the post-Golgi complex 
in vivo. Caloric restriction and leptin replacement increased the stability of the 
unprocessed protein form and restored the mature ABCG5/G8 form in ob/ob mice, 
repairing biliary cholesterol secretion. In fact, leptin administration alone increased 
ABCG5/G8 levels greater than those detected in wild type and pair-fed mice. However, 
there was no correlation between cholesterol transporter expression and biliary 
cholesterol concentrations, which possibly has a gallstone protective function. 
Cholesterol transport from the hepatocyte into the bile is a complex process which is 
still under investigation. Expressed in locations where bile acids are present in high 
concentrations, ABCG5/G8 acts as a floppase, transferring cholesterol from the inner to 
the outer leaflet of the plasma membrane [239]. In cell models, ABCG5/G8 cholesterol 
efflux is greatly dependent on mixed bile salt micelles which serve as a cholesterol 
acceptor [54]. Lastly, Harvey et al. have demonstrated that bile acids stimulate ATP 
hydrolysis in ABCG5/G8, possibly promoting an active confirmation of the complex. 
 
The exact mechanism by which leptin signaling normalized abundance of the 
transporters remains unknown. The uncoupling of biliary cholesterol concentrations 
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from ABCG5/G8 protein levels suggest that ABCG5/G8 transporter activity is regulated 
beyond abundance of mRNA and protein. Indeed, Cohen et al have reported that 
intracerebroventricular leptin administration in rats exerts the same effect in liver 
metabolism as intravenously administration, indicating that the hepatic response to 
leptin is conducted through the central nervous system [270]. However, direct 
activation of hepatic leptin signaling is not excluded since many of the leptin receptor 
(ObR) spliced forms were found also in liver. Additional experiments need to be 
conducted in order to be determined whether hepatic ObR-s independently triggers 
leptin signaling activation.  
 
Obesity and insulin resistance have been associated with ER-stress. It has been 
demonstrated that obesity creates ER-stress and initiates the unfolded protein response 
signaling pathways not only in peripheral tissues but in the hypothalamus, which 
sequentially leads to inhibition of leptin receptor signaling and promotes leptin 
resistance [219, 271]. Dietary restriction has been shown to have beneficial effects on 
obesity and insulin resistance, indicating possible ER-stress amelioration. Alleviation of 
ER-stress with the chemical chaperons PBA and TUDCA sensitized leptin receptor 
signaling in the hypothalamus and corrected hyperglycemia in ob/ob mice [219, 271]. 
However, this mechanism is not dependent entirely on CNS since PBA-treatment in 
db/db mice did not exert leptin-sensitizing effect in hypothalamus but decreased blood 
glucose levels, indicating direct effect of the molecular chaperone in liver. My results 
revealed that long term treatment (10 days) with TUDCA improved glycemic control and 
increased ABCG5/G8 transporter in db/db mice. However, the TUDCA effect was not 
genotype specific, since transporter protein levels were increased in wild-type mice, 
suggesting that the ER may possess a significant number of ABCG5 and ABCG8 
monomers, which shortly after synthesis are degraded and never become functionally 
active. However, little is known about TUDCA mechanism of action as a molecular 
chaperone. In addition, TUDCA belongs to the hydrophilic class of bile acids and 
although it is a very weak agonist it could possibly activate FXR suppressing Cyp7a1. 
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Moreover, acute liver perfusion with TUDCA increases biliary cholesterol secretion 
[239]. A similar bile acid, cholic acid, elevates ABCG5/G8 protein and mRNA abundance 
in wild-type mice and loses its effect in FXR knockouts [202]. Recently, an FXR response 
element was identified in the promoter unit of ABCG5 and ABCG8 [87]. However, in the 
current research increased ABCG5 and ABCG8 transcription upon TUDCA treatment was 
not detected. It could be speculated that TUDCA could act via the membrane bound bile 
acid receptor TGR5 since the activation and translocation of CFTR (ABCC7) is up-
regulated via TGR5 agonists [272]. Although biliary cholesterol composition was no 
different compared to wild type controls, TGR5 deficient mice, similar to ob/ob and 
db/db mice, had low biliary cholesterol saturation index and were resistant to gallstones 
when fed on lithogenic diet [273]. The existence of such mechanism regulating 
ABCG5/G8 complex requires further investigation.  
 
Both db/db and ob/ob develop premature insulin resistance and are a useful model in 
type 2 diabetes studies. To investigate whether a lack of insulin signaling on ABCG5/G8 
stability and exclude a possible influence of obesity, protein levels of the sterol 
transporters where evaluated in STZ-induced type 1 diabetic lean mice. Besides the 
differences in blood glucose levels, STZ mice demonstrated similar immunoreactive 
ABCG5/G8 levels, indicating that hyperglycemia is not sufficient to disrupt ABCG5/G8 
post-translational regulation. Conversely, insulin resistant and predisposed to gallstone 
formation LIRKO mice are characterized with increased expression of ABCG5 and ABCG8 
mRNA levels in a FOXO1 dependent manner resulting in accelerated biliary cholesterol 
concentration [86]. The discrepancy in the results could only be explained with the 
genetic background of the animal models and requires further investigation. 
 
Hypercholesterolemia and obesity in leptin axis defective db/db and ob/ob mice is 
fundamentally different from that seen in high cholesterol diet models, which is 
characterized by increased VLDL and LDL cholesterol. However, this model provides the 
opportunity to investigate the development of obesity and dyslipidemia on low 
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cholesterol diets. Ob/ob and db/db mice are one of the few mouse models of 
genetically predisposed hypercholesterolemia associated with leptin deficiency, where 
cholesterol accumulates in both HDL and a large HDL (HDL1) fractions. Leptin 
replacement in ob/ob mice restored biliary cholesterol elimination, increased both SR-BI 
and ABCG5/G8 proteins, and normalized plasma HDL [216, 241, 242]. Because the 
molecular mechanism of action initiated by the hormone remained elusive, it has been 
suggested that impaired apoprotein clearance is due to reduction in HDL receptor (SR-
BI) protein and mRNA abundance [241]. However, there is controversy as to whether 
SR-BI is changed [232]. In order to clarify the ambiguous data regarding protein and 
transcript SR-BI abundance in ob/ob and db/db mice, I used 2 cohorts of mice of 
different ages. Whereas older db/db mice had no change in HDL receptor expression 
compared to lean controls, the younger cohort had significant reductions in both SR-BI 
protein and mRNA. Unfortunately, my studies cannot provide sufficient explanation for 
the differences in SR-BI. It can only be concluded that there is no correlation between 
HDL levels in plasma and alterations in SR-BI abundance in db/db mice.  
 
Chapter 3 addresses the question as to whether acceleration of biliary cholesterol 
excretion by liver-specific adenoviral expression of ABCG5/G8 could correct dyslipidemia 
in db/db mice. In order to prevent possible reabsorption of cholesterol from the small 
intestine, db/db mice were supplemented with EZ, which blocks fractional absorption 
via the NPC1L1 dependent pathway. Consistent with the observations in Chapter 2, 
expression of adenoviral ABCG5/8 in liver accelerated biliary cholesterol secretion. 
However, ABCG5/G8 did not have an effect on plasma cholesterol levels. As a 
compensatory effect, the reduced regulatory pool of cholesterol in hepatocytes resulted 
in upregulated expression of cholesterol synthetic genes. However, I saw no increase in 
hepatic SR-BI or LDLR mRNAs. This observation suggests that biliary cholesterol 
excretion and hepatic uptake of HDL are functionally uncoupled. Whether this is a 
common feature or unique to db/db mice it is not known. Similarly, EZ treatment alone 
increased FNS drastically but failed to lower serum cholesterol in db/db mice. Only in 
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combination with EZ, ABCG5/G8 could partially correct the dyslipidemic profile in db/db 
mice maintained on low cholesterol diet. These observations underscore the role of 
biliary cholesterol secretion and fractional intestinal absorption on plasma cholesterol. 
Undoubtedly, plasma cholesterol regulation requires a cooperative relationship 
between the liver and intestine.  
 
Beyond its role in liver, ABCG5/G8 in the intestine is the primary defense for PS 
accumulation in the body. Sharing similar properties with cholesterol, dietary PS 
compete with cholesterol for micellar solubilization and thereby interfere with 
cholesterol absorption. PS dietary supplementation has been used as a cholesterol-
lowering therapeutic reducing LDL-cholesterol level. However, the action of PS goes 
beyond a simple replacement of cholesterol. PS are bioactive molecules with both cell-
type and sterol specific effects [255, 257, 258]. Conflicting research reports in humans 
and mice discuss the beneficial and deleterious effects of plant sterols on dyslipidemia 
and atherosclerosis [22, 251]. In fact, various reports demonstrate that different dietary 
sterols have diverse effects on SREBP-processing and LXR-target genes involved in 
cholesterol metabolism [257, 258]. ABCA1 and ABCG1, two cholesterol transporters 
involved in the initial step of RCT and oppose cholesterol accumulation in tissues, have 
been demonstrated to be influenced by PS. The studies in Chapter 4 report the effect of 
agLDL loaded with commonly encountered dietary sterols on mouse peritoneal and 
human macrophages. Stigmasterol increased expression of ABCA1 and ABCG1 and 
enhanced cholesterol efflux. Stigmasterol decreased the inflammatory response to 
uptake of modified lipoproteins, whereas sitosterol impaired the inflammatory response 
of agLDL loading. Conversely, sitosterol and campesterol did not change ABCA1 and 
ABCG1 abundance but tended to decrease cholesterol efflux. Campesterol had a modest 
inhibitory effect on cholesterol efflux from agLDL loaded macrophages to HDL. The 
increase in efflux to apoA-I and HDL in the presence of stigmasterol perhaps was 
predominantly facilitated by the upregulation of ABCA1 and ABCG1. However, the exact 
mechanism by which stigmasterol promoted cholesterol efflux from macrophages is 
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difficult to determine since stigmasterol interacts with at least two independent sterol 
sensing mechanisms (LXR and SREBP-2 dependent gene regulation). Likewise, the 
mechanism for suppression of inflammatory cytokine secretion remained unclear. This 
possibly is likely related to LXR activation based on the increase in LXR target genes by 
this sterol and the emerging role of LXR in the suppression of inflammation [269]. In 
contrast to other reports, stigmasterol did not have an effect on SREBP-2 transcription 
factor. Therefore, the suppression of LDLR by stigmasterol possibly relies on LXR 
dependent mechanism based on recent reports of LXR-mediated LDLR degradation 
[104]. Although my in vitro studies demonstrated beneficial effects of stigmasterol on 
macrophage function, the relative absorption and abundance of stigmasterol in PS 
supplements and functional foods suggests it is unlikely that stigmasterol will 
accumulates in sufficient quantities to have a significant positive impact on RCT or 
inflammatory pathways within macrophages.  
 
This research demonstrated that leptin signaling corrected hypercholesterolemia and 
restored hepatic ABCG5/G8 abundance post-transcriptionally. However, neither 
hepatic-specific ABCG5/G8 expression, nor inhibition of intestinal cholesterol absorption 
can normalize elevated plasma cholesterol in db/db mice. This finding identified not 
only distinct role for hepatic and intestinal ABCG5/G8 in modulating sterol metabolism 
but underscored the obligate cooperative relationship between liver and intestine in 
regulating plasma cholesterol content. Conversely, ABCG5/G8 in the intestine acts as a 
primary defense against PS absorption. Very low concentrations of biologically active PS 
influence the initial step of RCT pathway and the proinflammatory response in 
macrophage foam cells in vascular lesions. Understanding the nature of the interactions 
between cholesterol, PS, nuclear hormone receptors and ABC transporters involved in 
RCT is critical for the development of novel therapies for regulation of lipid homeostasis.  
 
 
Copyright © Nadezhda S. Sabeva 2011  
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APPENDICES 
 
ABBREVIATIONS 
 
ABCA1, ABCG1, ABCG5, ABCG8 ATP-binding cassette (ATP) transporter A1, G1, G5; G8; 
ACAT, acyl-CoA: cholesterol acyltransferase; apo-A1, apoB-48, apoB-100, apolipoprotein 
A1, B48, B100; CA, BA, bile acid; BS, bile salt; cholic acid; CDCA, chenodeoxycholic acid; 
CYP7A1, cholesterol 7α-hydroxylase; CYP8B1, sterol 12α-hydroxylase; CYP27A1, sterol 
27 hydroxylase; DCA, deoxycholic acid; ER, endoplasmic reticulum; FH, familial 
hypocholesterolemia; FC, free cholesterol; FNS, fecal neutral sterols; FXR, farnesoid-x-
receptors; HDL, high density lipoprotein; HMGS, HMG CoA synthase; HMGR, HMG-CoA 
reductase; IDL, intermediate density lipoprotein; LCA, lithocholic acid; LDL, low density 
lipoprotein; LDLR, low density lipoprotein receptor; LRH-1, liver receptor homolog-1; 
LRP, LDLR related protein; LXR, liver-X-receptors; MTTP, microsomal triglyceride transfer 
protein; NPC1L1, Niemann-Pick disease type C1 gene-like 1; PL, phospholipids; PS, plant 
sterol; PBA, 4-phenyl butyric acid; SREBP, sterol response element binding protein; SRE, 
SREBE response element; SR-BI, scavenger receptor class B type 1; TD, Tangier disease; 
TUDCA, tauroursodeaxycholic acid; VLDL, very low density lipoprotein; UPR, unfolded 
protein response; 7α-OH-C, 7α-hydroxycholesterol; 25-OH-C, 25-OH cholesterol; 
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EXPERIMENTAL PROCEDURE PROTOCOLS 
 
A: PREPARATION OF MEMBRANE PROTEINS FROM TISSUES 
Solutions: 
Membrane Buffer:     500 ml 
20 mM Tris-Cl (pH 7.5)    10 ml 1 M Tris 
2 mM MgCl2     1 ml 1 M MgCl2 
0.25 M sucrose      42.8 g 
Add Tris and MgCl2 to 400 ml water, pH to 7.5.  Add sucrose and qs to 500 ml. Store at 
4oC for up to 1 month. Add protease inhibitors immediately prior to use. 
1:100  Protease Inhibitor Cocktail 
4X Protein Sample Buffer:   500 ml  
120 mM Tris base    60 ml 1M Tris 
40 mM EDTA     40 ml 1M EDTA 
4% SDS     20 g  
20% glycerol     100 ml 
0.025% bromophenol blue   125 mg 
Add Tris, EDTA , SDS and 25 ml water and pH to 6.8.  Add bromophenol blue and 
glycerol and qs to 50 ml.  Membrane proteins are typically solubilized in 3% SDS.  
1X Protein Sample Buffer:  
4X Buffer     2.5 ml 
10% SDS     2 ml 
Water      5.5 ml 
 
Protocol: 
1. Weigh out tissue (pulverized) 0.2 g for everything except fat (for fat use 0.4 g) into 
14 ml Falcon (2059) tubes containing 1.2 ml of membrane buffer.  
2. Homogenize approx. 1 min and put on ice (Turax Homogenizer) 
3. Spin for 10 min., 3500 rpm @ 4 oC (~2000 x g) 
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4. Remove 1 ml of supernatant.  Do not take any of the pellet or fat/junk that may be 
on top of supernatant. 
5. Place in centrifuge tube for Ti 50.4 (3 ml) rotor. 
6. Centrifuge at 100,000 x g (30, 500 rpm), 60 min, 4oC. 
7. Decant supernatant.  Leave tube upside down to drain for 1 min.   
8. Suspend pellet in 1X sample buffer (100 µl - 250µl). Use pipette or insulin syringe 
(Baxter 59505-1) to completely resuspend pellet. 
9. Transfer to 1.5 ml eppendorf tube. Store at –20 oC. Do not add β-ME until preparing 
samples for gel. 
10. Determine protein concentration with BCA. Use 2-5 µl in BCA protein assay 
11. Immediately prior to SDS-PAGE, add β-ME to a final concentration of 1.2% and heat 
at 95oC for 5 min. 
12. Load 50 ug protein/ lane. 
 
 
B: SDS PAGE 
Solutions: 
Acrylamide: bisacrylamide – 37.5:1 
Lower Tris 
 500 ml 
Tris-base (1.5 M) 90.75 g 
SDS (0.4 %) 20 ml (10%) 
ddH2O qs to 500ml 
pH to 8.8 with HCl and store at 4oC 
 
Upper Tris 
 200 ml 
Tris-base (0.5 M) 29.2 g 
SDS (0.4 %) 0.8 g 
ddH2O qs to 200ml 
pH to 6.8 with HCl and store at 4oC 
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10X Running Buffer 
 1.0 L 
Tris-base (1X: 25 mM) 30 g 
Glycine (1X: 192 mM) 144 g 
SDS (1X: 0.1% w:v ) 10 g 
ddH2O qs to 1.0 L 
10X Transfer Buffer 
 1.0 L 
Tris-base (25 mM) 30 g 
Glycine (192 mM) 144 g 
ddH2O qs to 1.0 L 
No need to pH; pre-chill 1X to 4oC. 
 
5X Sample Buffer 
 50 mL 
Tris Base (0.3125 M) 1.89 g 
SDS (2.5%) 12.5 ml of 10% stock 
glycerol (50%) 25 ml 
bromophenol blue (0.125%) 62.5 mg 
ddH2O qd to 50 ml 
 
Protocol: 
1. Wash glass spacers and combs in EtOH, and assemble plates. 
2. Pour resolving gel to 0.5 cm below comb. 
 
Mini Gels (18ml/2 gels) 
Percent Gel 10 % 
ddH2O 9.0 ml 
lower tris 4.5 ml 
40% acryl-
bis 
4.5 ml 
10% aps 180 µl 
Temed 20 µl 
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1. Overlay with water saturated isobutanol and allow to polymerize. 
2. Rinse top of gel with distilled H2O.  Remove remaining water with filter paper. 
3. Insert comb and pour stacking gel. 
 
Mini (6 ml) 
 3.0% 4.0% 
ddH2O 4.0 ml 3.9 ml 
upper Tris 1.5 ml 1.5 ml 
acryl-bis 450 µl 600 µl 
10% APS 60 µl 60 µl 
TEMED 10 µl 20 µl 
 
1. Allow to polymerize and submerge in 1X Running Buffer until use. 
2. Heat samples to 95oC for 5 min. and quick spin. While samples are heating, remove 
comb and rinse wells with running buffer. 
3. Run at 50 mAmps (constant current)  
4. Stain gels overnight with coomassie and distain. 
 
Transfer to nitrocellulose membrane for western blot 
1. Remove stacking gel and soak in 1X Transfer Buffer for 5 min. 
2. Cut two pieces of filter paper and 1 piece of nitrocellulose membrane for each gel. 
3. Pre-wet nitrocellulose membrane in 1X Transfer Buffer for 5 min. 
4. Build sandwich at 4oC Transfer Buffer, and run at 200 mAmps (constant current) for 
2hrs. 
5. After transfer, trim excess membrane and allow drying at room temp. 
 
Transfer to nitrocellulose membrane for western blot 
1. Remove stacking gel and soak in 1X Transfer Buffer for 5 min. 
2. Cut two pieces of filter paper and 1 piece of nitrocellulose membrane for each gel. 
3. Wet in 1X Transfer Buffer for 5 min. 
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4. Build sandwich in cold (4oC) Transfer Buffer, and run at 200 mAmps (constant 
current) for 2 hrs.  
5. After transfer, trim excess membrane and do not allow nitrocellulose to dry  
 
 
C: WESTERN BLOTTING 
Solutions: 
10X TBS     1 L 
Tris-base (200 mM)   24.2 g 
NaCl (1.37 M)    80.0 g 
ddH2O     qs to 1 L 
pH to 7.6 with HCl 
 
10% Tween 20    500 ml 
Tween 20    50 ml 
TBS     450 ml. Store at 4oC 
 
TBST (Wash Buffer)   1 L 
10% Tween 20 (0.2 %)  20 ml 
10X TBS     100ml. qs to 1 L 
 
Blotting Buffer   100 ml 
Carnation dry milk (5 %)   5.0 g 
10% Tween 20 (0.2 %)  2 ml 
1X TBS     qs to 100 ml 
Alternatively, add 5 g dry milk to 100 ml Wash buffer. 
 
Stripping Buffer    1 L 
Tris-base (62.5 mM)   1M 62.5 ml 
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SDS (2.0 %)    20 ml 10% SDS 
β-mercaptoethanol (100 mM) 78 ml 
Add Tris to 750 ml water and pH to 6.7. Add SDS, β-ME and qs to 1L. 
 
Protocol: 
1. Block membrane with Blotting Buffer for 30 min at room temp. 
2. Pour off Blotting Buffer and incubate with 1o antibody for 1 hr at room temp., or 4oC 
overnight. 
3. Remove 1o antibody and wash 15 min at room temp.  Change Wash Buffer every 5 
min. 
4. Incubate with 2o antibody for 30 min at room temp. 
5. Remove 2o antibody and wash 15 min at room temp.  Change Wash Buffer every 5 
min. 
6. Wash with TBS for 5 min. 
7. Develop with ECL reagent 
8. Immediately prior to use combine 3 ml of reagent A with 3 ml reagent B for each 
membrane and vortex. Place membrane in a clean dish, add ECl reagent and 
incubate for 5 min. at room temp. Wrap membrane in food service film and 
immediately expose to film (typically 30 s, 60 s, 3 min. and 5 min.; however, some 
reactions may take longer to develop). 
 
 
D: STEROLS ANALYSIS IN BILE/PLASMA 
1. Put 100 l ISTD (internal standard, 100l   100 g/ml 5-cholestane =10 g 5-
cholestane. ISTD is 100 g/ml 5-cholestane) in culture tubes (10 g 5-cholestane). 
2. Pipette 10 l bile/plasma in tubes. 
3. Put freshly prepared 1 ml hydrolysis solution in each tube. KOH stock solution: 10 
mol/L. Every 6 ml KOH stock solution mixed with 94 ml Ethanol. 
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4. Heat at 90-100C for two hours for saponification. (During saponification, vortex 
tubes) 
5. Cool down to room temperature. 
6. Put 1 ml of distilled water in each tube and vortex. 
7. Put 2 ml petroleum ether in each tube and vortex vigorously for 10 to 15 seconds.  
8. Centrifuge at 2800 rpm for 15-20 min. 
9. Remove the upper phase (petroleum phase) to a test tube. 
10. Put 2 ml petroleum ether in each tube and vortex vigorously for 10 to 15 seconds.  
11. Centrifuge at 2800 rpm for 15-20 min. 
12. Remove the upper phase (petroleum phase) to the same test tube and dry down 
under nitrogen stream.  
13. Add 100 l Tri-sil reagent in each test tube and mix it. 
14. Transfer it to GC vial and heat at 75C for 15-30 min. 
15. Cool down to room temperature and transfer the solution into GC insert and put the 
insert back to GC vial. 
16. Run samples on GC-MS. 
 
 
E: HEPATIC LIPIDS EXTRACTION PROTOCOL  
Folch reagent/BHT:  280 ml chloroform + 140 ml methanol (2:1) + 42mg BHT (to 
100ug/ml) 
1. Prepare Folch reagent/BHT. 
2. Cut 100 mg of liver (0.1 g) and put in dounce test tube. Homogenize using dounce 
pestle. 
3. After three/four ups and downs, insert 1 ml of MBTS/OG and homogenize a little 
more. Put the dounce test tube in ice and wait 30 min for extraction. 
4. Add 2 ml of Folch/BHT reagent. Vortex for 3 x 10 sec (vortex all samples once, then 
twice, then three times. Leave 5 min. waiting time between each vortex). 
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5. The solution should look like floating milky-powders right now. Centrifuge at 2000 
rpm for 10 min at RT. (RPM = 2000, RCF = 850, Rotor (the big wheel and its name) = 
S-5.1, Time = 10 min, Temp = 22ºC). 
6.  After centrifugation, the solution should have three phases  
 methanol phase 
 protein & nucleic acid phase 
 chloroform and FA phase at bottom  
7. Move majority of LOWER PHASE to reaction tube with glass pipet, dry under N2 to 
about 100 µl. 
8. Add 1 volume (200 µl) of 1% Triton x 100 in CHCl3. 
9. Dry down by N2. 
10. Add 0.5 volume (100 µl) of H2O. 
11. Measure cholesterol and TG, and PL with Wako Kit. 
 
 
F: LIPID EXTRACTION FROM CELLS 
Protocol: 
1. Rinse plates 2X with 3 mL PBS (4oC). 
2 Scrape dishes in 3 mL of PBS and transfer to a 12x75mm glass tube. 
3. Vortex and take a 100 L aliquot for protein determination. 
4. Centrifuge at 1000 x g for 5 min. (4oC), and aspirate PBS. 
5. Add 2 mL 3:2 hexane: isopropanol. Vortex! 
6. Incubate and for 10 min. (20oC). 
7. Centrifuge at 1000 x g for 5 min. (4oC), and transfer supernatant to a fresh 12x75 
mm tube 
8. To pellet, add 2 mL 3:2 hexane: isopropanol. Vortex! 
9. Incubate and for 10 min. (20oC). 
10. Centrifuge at 1000 x g for 5 min. (4oC), and transfer supernatant to 12x75 mm tube 
(7). 
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11. Evaporate to dryness under N2 (g). 
12. Solubilize the extracted lipids in a suitable solvent. 
For Storage: Suspend in 500 L of CHCl3, flush with N2 (g) and store at -20
oC 
For TLC: Suspend in 200 L of 1:1 CHCl3:CH3OH (must be used immediately) 
For Enzymatic Cholesterol Assays:  Suspend in 2 mL 1% Triton in CHCl3.  Solution can be 
stored at -20oC.  
Notes: If the cells are in 6-well or 12-well plates, Hexane: Isopropanol 1mL or 0.5mL, 
respectively can be added directly to the plate.  After extraction, aspirate the solvent 
and proceed with step 11. 
 
 
G: FECAL NEUTRAL STEROL ASSAY 
1. Let samples dry on 37ºC for couple days. Grind them. 
2. Weight out exactly 0.25g aliquot of dried, ground stool and place in a f. a. tube. Add 2.5ml 
ethanol, vortex, then add 0.5ml of 10N NaOH and vortex again. 
3. Add 2.5ml water and 2.5ml ethanol to the dried residue, place tubes in water bath at about 
45-50ºC for a few min. Remove tubes, vortex, then add 2.5ml PE (petroleum ether) and 
0.5ml of 5-cholestene standard in hexane (1.0mg/ml). Shake tubes vigorous for about one 
min. Centrifuge tubes after balancing. Spin for 10min @ 1500rpm until the phases fully 
separate. 
4. If the sample were derived from animals fed diet with no added cholesterol than take 1 ml 
aliquot of PE phase for GC. For samples from cholesterol-fed animals take 1 ml PE aliquot. 
5. Pipette PE aliquot into 12 x 75mm glass disposable tubes, dry under air, and then redissolve 
sterols in 400 µl hexane. Transfer 2 x 200µl to GC vial. 
6. Run samples on GC at a temperature of 280ºC and using a 10 min run time. Run duplicates 
of the following standard mixtures before and after the samples. 
a) Cholesterol: 5-cholesten (1:1). Ratio of peak areas should be 0.88-0.90 
b) β-coprostanol: 5-Cholestene (1:1). Ratio should be 0.90-0.91 
c) α-Cholestanone: 5-Cholestene (1:1). Ratio should be 0.95-0.96. 
7. Each of these standards mixtures is prepared using 20mg of each sterol per 100ml hexane.  
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The peak area for 5-cholestene should be about the same for all samples. If not, shake tubes 
again vigorously, centrifuge again and repeat the assay on another aliquot of the upper phase. 
sample  =  x 
std     1 
8. Calculate the amount of cholesterol, coprostanol and cholestanone and sum these to obtain 
the total neutral sterol content of the stool sample.  
 
Sterol standards for Fecal Neutral Sterol 
5-cholestene        Sigma 
5α-cholestan-3-one (Cholestanone)    Steraloids 
5α-cholestan-3β-ol (coprostan-3-ol) coprostanol   Sigma 
 
 
H: CHOLESTEROL LOADING AND ANALYSIS IN THP1 CELLS 
Culture medium: RPMI 1640 + 10% FBS + 1%P/S 
Assay Medium: RPMI 1640 + 1%P/S+ 1% FBS alone and either 100 µg protein/ml AgLDL 
+/- plant sterols.  
 
Day0 
1. Culture THP 1 cells @ 37 C in 10 cm dish / 9x106. (Control; AgLDL + 20 µg/ml 
cholesterol; AgLDL + 20 µg/ml stigmasterol; AggLDL+20 µg/ml sitosterol) 
2. Use RPMI 1640 medium +10% FBS +1%P/S+ 200 µg/ml PMA 
Day3 
1. To measure the sterol loading, macrophages were incubated for 3-4 days at 37C in 
culture medium containing 1% FBS alone and either 100 µg protein/ml AgLDL +/- 
plant sterols.  
2. Change the sterol medium every3-4 days 
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Aggregation of LDL 
LDL stock  5.06 mg/ml 
 Add 3mg LDL /30 ml assay medium (5ml in each dish) 
 Split this volume in 3, 50 ml polypropylene conical tubes (30 X 115 mm) Falcon. 
 Add the appropriate amount of sterol in the desired concentration. 
 Aggregate by vortex 1 min on ice to break up large aggregates and passed through a 
0.45 µm filter. This produces small (~ 30-75 nm) aggregates that produce maximal 
uptake and lysosomal delivery. 
Day 6 
1. Aspirate the medium. 
2. Wash with 2 x PSB. 
3. Add 1 ml Membrane buffer.  
4. Prepare membrane samples for western blot 
5. Blot for AbCG1, ABCA1. 
 
 
I: CELLULAR CHOLESTEROL EFFLUX ASSAY ([3H]-CHOLESTEROL LABELED CELLS) 
The following protocol was developed for the efflux of cellular cholesterol from THP1 
cells to HDL. Other extra-cellular cholesterol acceptors may be substituted for HDL. 
Many cell types have been examined for cellular cholesterol efflux. For other cell types 
simply substitute their respective media for RPMI. 
 
I. Reagents 
Growth Medium: RPMI 1640 + 10% FBS + 1% P/S + 10ng/ml PMA 
Labeling Medium: RPMI 1640 + 10% FBLPPS + 1% P/S + 1 µCi/ml [3H]-Cholesterol 
(NEN #NET 725) +/- 100µg/ml agLDL+/- 20 µg/ml plant sterols 
 
STOCK [3H]-Cholesterol 1.0 µCi/ml 
    57.6 µCi /mmol  
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    FW 386.7 
 
Assay Medium: RPMI 1640 + 0.2% FAF-BSA (Roche #100 377) 
PBS: Dulbecco’s PBS without Mg2+/Ca2+ 
PBS-FAF BSA: PBS + 0.02 % FAF-BSA 
Solubilization Solution: 0.1N NaOH + 0.1% SDS 
II. Cell Culture (Day 0) 
All assays are done in triplicate.  Seed cells at7 x106 cells/well in 12 well plates in Growth 
Medium (37oC, 8.8% CO2) 
III. Labeling of Cells (Day 3) 
a. Aspirate growth medium 
b. Wash cells 2X with PBS (37oC) 
c. Add 1 ml Labeling Medium 
 
Row # Labeling Medium AgLDL Plant sterols 
#1 + + ─ 
#2 + + T comp 
#3 + + Stigmasterol 
#4 + + Β-Sitosterol 
 
d. Incubate 12-16 h (37oC, 8.8% CO2) 
IV. Efflux Assay (Day 4) 
a. Aspirate Labeling Medium (Store all liquid radioactive waste in appropriate 
container) 
b. Wash 2X with Assay Medium (37oC) 
c. Add 1 ml Assay Medium  
d. Incubate for 1 h (37oC, 8.8% CO2) 
e. Aspirate medium 
f. Add 0.7 ml of Assay Medium containing desired amount of 30 µg/ml apoA-I or other 
acceptor  
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g. Incubate 100 µl from each well and pool in the appropriate 1.5 ml tube for desired 
time (37oC, 8.8% CO2). 
 15 min; 30 min; 60 min (1 hour); 120 min (2 hours); 240 min (4 hours); 480 min ( 8 
hours) 
 
All subsequent steps should be done on ice or in the cold room with pre-chilled 
solutions 
h. Transfer Assay Medium to 1.5 ml tube 
i. Centrifuge at 1000 x g for 10 min 
ii. Transfer supernatants to scintillation vials containing 10 ml scintillation 
cocktail 
i. Wash cells 3X with PBS-FAF BSA (4oC) 
j. Wash cells 2X with PBS (4oC) 
k. Add 0.5 ml Solubilization Solution to cells and incubate on rotator (30 min, RT). 
l. Transfer solubilized cells to 1.5 ml centrifuge tube 
V. Data analysis 
a. Determine protein concentration of solubilized cells 
b. After protein assay is complete, transfer solubilized cells to scintillation vials 
containing 10 ml scintillation cocktail 
c. Count on beta counter (Program #44: 2 min, Sigma, 2%, H#, SL DPM) 
d. Express counts from medium and cells in pmol cholesterol /mg total cell protein to 
normalize for cell numbers 
e. Calculate Efflux as percent of total cellular cholesterol (Medium/ Cells + Medium) 
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